Introduction
Age-related macular degeneration (AMD) is the leading cause for irreversible visual impairment and blindness (i.e. best corrected visual acuity (BCVA) < 0.3 in better eye) in the developed countries. Its prevalence is expected to increase in the future (Pascolini et al. 2002; Congdon et al. 2004; Rein et al. 2009 ). The disease affects mainly the central or macular area of the eye (Fig. 1 ), the part of the eye which is responsible for detailed vision. The macula has the highest concentration of photoreceptor cells, and thus AMD causes a loss of central vision whereas the peripheral vision usually remains normal (Cheung & Eaton 2013) . The loss of vision is directly linked to the damage and death of photoreceptor cells; this is primarily caused by degeneration of the retinal pigment epithelium ( Fig. 2 ; Klettner et al. 2013) . RPE is a part of the blood-ocular barrier and furthermore it performs many functions such as transporting nutrients and oxygen between the retina and the choroid as well as producing growth factors and cytokines (Cheung & Eaton 2013) . Phenotypically AMD can be divided into dry (atrophic) and wet (exudative) forms ). Dry AMD is more common and is responsible for 80-85% of all cases (Kaarniranta et al. 2009a ). In the early stages of dry AMD, one can detect small, yellow deposits called drusen (sing. druse) in the fundus of the eye. These deposits are mainly composed of protein derivates, essentially cellular waste products, and they gradually grow in size from small, <63 lm diameter deposits to larger than 125 lm deposits (Bird et al. 1995) . The dry form usually progresses slowly over years (Sunness et al. 1997; ). The wet form is more aggressive as it can progress in a much shorter time frame, days or weeks, leading to a complete loss of central vision if not treated (Klettner 2014) . In the wet form of AMD, new, abnormal blood vessels (so-called neovascularization) grow from the choroidal capillaries through Bruch's membrane into the retina. These new blood vessels tend to leak, leading to edema in the retina and damage to the photoreceptor cells (Kaarniranta et al. 2003; Mannermaa et al. 2007) . Currently, there is no cure for dry AMD, although nutrient supplements are usually recommended (AREDS 2000) . The wet form is treated with anti-VEGF agents, which may stop or retard the progression of the disease (Klettner 2014) .
Although the pathogenesis of AMD is still partly unknown, the decline of cellular autophagy (literally meaning 'self-eating') plays a key role in the development of AMD (Kaarniranta et al. 2011) . Autophagy is a central degradation process in mammalian cells (Lilienbaum 2013) , and it is known to be impaired in aged RPE cells (Li et al. 2008 ).
The purpose of this study was to investigate the role of autophagy in the regulation of proteostasis in in vitro and in vivo models and in human samples. We postulate that autophagy might be a novel therapy target in AMD.
Review of Literature
Age-related macular degeneration Age-related macular degeneration is the leading cause of visual impairment in the developed countries (Pascolini et al. 2002) . It has been estimated that about 50 000 Finns have BCVA (best corrected visual acuity) below of 0.3 and approximately 40% of these suffer from AMD (Ojamo 2014 ). The prevalence of fundus findings (e.g. drusen) correlating with AMD has been shown to be as high as 20% in individuals aged 43-86 years, although this may not correlate with clinically significant AMD. Approximately 1.6% of the population develop late stage AMD (Beaver Dam eye study; Klein et al. 2014 ). The prevalence of AMD increases exponentially with every decade after 50 years (Cheung & Eaton 2013) . Globally the annual costs associated with AMD are estimated 340 billion US dollars (Klein et al. 2010; Biarn es et al. 2011 ). The loss of central vision can be devastating and crippling to patients and cause other severe complications such as falling down (Klein et al. 2003) and depression (Casten et al. 2004) . Considering its impact on quality of life, then AMD appears to be at the same level as other chronic diseases (e.g. chronic cardiac diseases or arthritis; Williams et al. 1998 ).
Etiology
Age-related macular degeneration (AMD) is a multifactorial disease and it evolves from complex genetic and environmental interactions. However, aging is the strongest risk factor for AMD. The risk increases exponentially with every decade after 50 years of age (Rudnicka et al. 2012) . In particular, the Caucasian race has been documented to be at risk for AMD (Klein et al. 2004 ). Since females usually live longer than males, they have an increased risk of developing AMD (Hyman & Neborsky 2002) . However, many epidemiological findings are controversial and might be based on population differences (Klein et al. 2004) . Smoking, hypertension, high dietary intake of fats, obesity and low intake of anti-oxidants and zinc have been shown to be associated with the disease (Maquire et al. 1997; Klein et al. 2001; Seddon et al. 2003 ; Thornton et al. 2005) . Several studies have revealed that over 70% of AMD cases are associated with polymorphisms in complement factor H (CFH), complement factor B and complement component 2 (C2) genes (Gold et al. 2006; Fritsche et al. 2013 ). Genetic pathways have been linked to complement systems, cholesterol and lipid metabolism, oxidative stress and angiogenesis (Ratnapriya & Chew 2013) .
Clinical findings and diagnostic criteria
The clinical examination can incorporate slit-lamp biomicroscopy, optical coherence tomography (OCT; Fig. 3 ) and fluorescein angiography (FAG). The first signs of AMD are small, white-yellow deposits called drusen situated between the RPE and the underlying basement membrane (Bruch's membrane; Cheung & Eaton 2013) . Drusen can be subdivided according to their size and appearance (Fig. 4) . Small drusen have a diameter less than 63 lm, intermediates are sized between 63 and 125 lm and large are over 125 lm in diameter (Bird et al. 1995; Klein et al. 2014) . In addition to their size, drusen can be classified based on their form. Hard drusen are small and have well defined margins where as soft ones are larger and have diffuse, cloudlike margins (Sarks et al. 1994) . At the same time with drusen RPE hypo-and/ or hyperpigmentation can be observed by fundus biomicroscopy (Fine et al. 2000) . The presence of choroidal neovascularization is a clinical criterion for wet AMD. Retinal hemorrhages and oedema can be observed by biomicroscopy and OCT (Fig. 5 ). FAGimaging shows leaking new blood vessels sprouting from the choriocapillaries ).
The Age-Related Eye Disease Study (AREDS) criteria (Age-Related Eye Disease Study Research Group 2000) are widely used in the AMD classification. According to AREDS, AMD can be divided into early, intermediate and late forms of AMD. In the early stage, there are several small drusen, nonextensive intermediate drusen or pigment abnormalities (hypo/hyperpigmentation) at least in one eye. In the intermediate stage,
there are large drusen, several intermediate drusen or noncentral (i.e. not affecting the fovea) geographic atrophy at least in one eye. The term 'geographic atrophy' is used when there are no RPE or photoreceptor cells in the area of interest (Bird 2010) . Late stage disease has geographic atrophy, choroidal neovascularization and/or fibrosis in the fovea. Depending on the severity level of AMD, patients experience difficulties in reading, facial recognition and in driving a motorized vehicle (Fine et al. 2000) .
Pathogenesis
The fundamental cellular pathophysiological events are increased oxidative stress, protein aggregation and inflammation (Fig. 4) . RPE cells function as the caretakers of the retinal outer segment which is mainly composed of photoreceptors. They maintain the blood-retina-barrier, regulate ion balance, participate in the visual cycle and secrete several growth factors (Kinnunen et al. 2012) . They also have a distinctive role in the clearance of used photoreceptor outer-segments (the part of the retina that wears out during the visual cycle) by a process called phagocytosis (Strauss 2005) . During phagocytosis, a cell engulfs and takes up a particle within a plasma-membrane envelope (a form of endocytosis; Gordon 2016).
The RPE cells are constantly exposed to oxidative stress. Firstly, they phagocytose lipid-rich retinal outer segments derived from photoreceptors, rods and cones. This predisposes the RPE to oxidation because the process generates reactive oxygen species (ROS; Gordon 2016) . At the same time, the RPE is exposed to light combined with a high oxygen consumption due to its high metabolic activity. All of these properties increase oxidative stress (Tate et al. 1995; Beatty et al. 2000) . The dysfunction of phagocytosis leads to a failure in the clearance of used photoreceptor outer segments, which on the other hand causes intracellular accumulation of lipofuscin, a lipid-protein-aggregate (Kennedy et al. 1995) . Lipofuscin is the product of the oxidation of unsaturated fatty acids (Algvere et al. 2016) . Around 90% of the accumulated lipofuscin in the RPE originates from the retinoids (rich in unsaturated fatty acids) used in the visual cycle (Sparrow et al. 2003) . Lipofuscin is a toxic compound, which increases the formation of ROS when exposed to light (Algvere & Seregard 2002; Roth et al. 2004) . Vitamin A -derived fluorophores in the lipofuscin pigment cause protein misfolding and inhibition of mitochondrial respiration (Algvere & Seregard 2002; Brunk & Terman 2002 ). In addition, nuclear factor kappaB, a master regulator of both innate and adaptive immune systems is triggered by many stimuli such as the accumulation of advanced glycation end-products (AGE) and receptor for AGE (RAGE). Interleukin 6 (IL-6) is transcriptionally regulated by nuclear factor kappaB and it is a regulator for choroidal Lipofuscin accumulation leads to lysosome and mitochondrial deficiency. This is worsened by the constant oxidative stress (OS). Oxidative stress also causes increased protein misfolding, which is impaired in AMD by a dysfunction of molecular chaperones (Hsp). These properties lead to protein aggregation and ultimately to inflammation, which in turn leads to drusen formation. The formation of drusen decreases cellular homeostasis, and the vicious cycle is completed. neovascularization (CNV; Izumi-Nagai et al. 2007 ). Interestingly, activation of RAGE in RPE produces vascular endothelial growth factors (VEGF) and RAGE is highly accumulated in the late phase AMD but not in normal retina. Thus, the AGE-RAGE-nuclear factor kappaB axis can lead to CNV (Howes et al. 2004; Bierhaus et al. 2005; Paimela et al. 2007; Oskolkova et al. 2008; Javitt & Javitt 2009 ). RPE degeneration caused by the dysfunction of phagocytosis, protein degradation and metabolic insufficiency all play a key role in the pathogenesis of AMD (Kinnunen et al. 2012 ). This loss of retinal homeostasis distinguishes AMD from the normal degenerative changes that occur with aging (Ardeljan & Chan 2013) .
Drusen are the hallmarks of AMD; they have both intra-and extraocular sources (Buschini et al. 2011) . Components, such as ubiquitin, integrins, beta-amyloid, complement components, collagens and fibronectins have been identified in drusen (Johnson et al. 2000) . Interestingly, beta-amyloid has been identified in the senile plaques of individuals with Alzheimer's disease (AD). AD also shares pathophysiological similarities with AMD e.g. oxidative stress and degeneration leading to cell death; in fact it has been hypothesized that AMD and AD might be two representations of the same disease (Vladan & Panfoli 2012) . Regardless of the AD connection, it seems that drusen are caused by local inflammation, activation of the complement system and systemic immune (e.g. acute, autoimmune, coagulation, cytokine etc.) mechanisms (Hageman et al. 2001 ). The formation and accumulation of drusen causes hypoxia in the retinal pigment epithelium by decreasing the flow of oxygen from the choriocapillaries to the RPE, which secondarily leads to degeneration (Arjamaa et al. 2009 ).
Current treatments of AMD
Currently, there is no treatment available for dry AMD (Bowes et al. 2013 ). Oral supplementation with vitamins C and E, lutein, zeaxanthin and zinc according to AREDS and The AgeRelated Eye Disease Study 2 (AREDS2) formulation may delay the progress of AMD from earlier stages to wet disease but not to late stage atrophic AMD (AREDS 2001; AREDS2 2013) .
Laser photocoagulation of drusen has also been considered as a therapeutic device, because the disappearance of drusen has been observed after laser photocoagulation (Cleasby et al. 1979; Gross-Jendroska et al. 1998) . In 2009, one study group showed that laser photocoagulation of drusen was not useful, although it had no adverse effects, and thus it could not be recommended (Frennesson et al. 2009 ). This was later confirmed by a Cochrane review (Virgili et al. 2015) .
Some years ago, photodynamic therapy (PDT) was widely used in the treatment of wet AMD. In PDT-treatment, intravenously administered verteporfin (a benzoporphyrin derivative) is activated with an infrared laser beam focused above the macula. Verteporfin concentrates in new blood vessels and its activation triggers the formation of free oxygen radicals, ultimately leading to local thrombosis (Scott & Goa 2000) . The use of PDT is less effective than treatment with VEGF inhibitors but it reduces the loss of vision (Kaiser 2006) . In rare cases, laser photocoagulation of CNV can be used as a treatment, but in those cases the lesion must be at least 200 lm from the fovea because of the risk of central scotoma (Macular Photocoagulation Study Group 1991) . PDT is still a worthwhile option, for example, in cases where intravitreal injections are relatively (post-endophthalmitis, inflammation) or absolutely contraindicated (such as in macular ischemia).
Currently anti-VEGF injections are the first option for the treatment of wet AMD (Klettner 2014) . Clinicians can administer four different VEGF-therapies for AMD (Cheung & Eaton 2013) . Bevacizumab was first developed for the treatment of metastatic colorectal carcinoma, but subsequently has been used intravitreally for the treatment of wet AMD as an off-label product (Brechner et al. 2011) . Bevacizumab binds to all active VEGF-A isoforms (Klettner & Roider 2009 ) and its safety and efficacy have been proved (Tufail et al. 2010) . Ranibizumab is the binding fragment of bevacizumab; it works similarly to bevacizumab binding to all active VEGF-A isoforms (Ferrara et al. 2006) . Aflibercept differs from the former two agents by binding to two sites on the VEGF-dimer and thus trapping the growth factor. It also binds placental growth factor as well as all VEGF-A isoforms (Dixon et al. 2009 ). The fourth currently used drug is pegaptanib, which prevents the VEGF-165 isoform from binding to VEGF receptors (Singerman et al. 2008) . Because the efficacy of pegaptanib has been proved to be inferior to the other options, it is used as a secondline therapy (Cheung & Eaton 2013) . In all of the therapies, an interval of 4-8 weeks is generally applied although there are studies that recommend intravitreal injections to be given at 6-7 week intervals (Zhu et al. 2008) . In cases of resistance, treatment time-outs and/or switching between therapeutics can be useful (Bressler 2009; Arjamaa & Minn 2012) .
Trials for new AMD treatments
Since AMD has a multifactorial background, several targets for treatment have been proposed. The systemic use of an antibody against amyloid-beta in a mouse model seems to preserve RPE integrity and visual function (Ding et al. 2011) . Complement-based therapeutics, such as inhibitory peptides, antibodies, aptamers, corticosteroids and non-steroidal anti-inflammatory drugs, have been widely studied but without any breakthroughs (Ambati et al. 2013) . For example, a recent phase II trial showed that C5-inhibition was well tolerated but did not reduce the progression of geographic atrophy (Yehoshua et al. 2014) . Interestingly, inactivation of the complement factor D reduced geographic atrophy by approximately 20% (Jack et al. 2016) . As oxidative stress has a significant role in the development of AMD, therapeutic agents aimed towards lessening oxidative stress are being evaluated. A topically administered disubstituted hydroxylamine, an anti-oxidant and anti-inflammatory molecule, was proven to be tolerated but not beneficial in a phase II trial. As beta-amyloid is known to be proinflammatory, topically and intravenously delivered agents targeted against beta-amyloid are undergoing phase I and II trials on the hypothesis that this would be RPE protective (Hanus et al. 2016) . Agents targeting the visual cycle and lipofuscin, especially against the formation of vitamin A derivatives, are also under evaluation (Hanus et al. 2016; Jack et al. 2016 ). Since AMD is associated with protein accumulation and dysfunction of RPE autophagy activity, autophagy regulating kinases are also thought to be potential targets for the treatment .
It has also been proposed that atrophic AMD would be amenable to treatment with stem cells. Stem cellderived RPE would replace the damaged RPE and provide sufficient function to ensure the survival of other retinal cells. The first clinical trials with human embryonic stem cell-derived RPE cells transplanted subretinally were promising (Becker et al. 2012) and phase I/II trials showed improvement of BCVA (Schwartz et al. 2015) . Further results are awaited.
Current models for AMD
Cultured RPE cells are used in in vitro studies with most of them being mouse, rat, pig and human primary and secondary cell cultures and cell lines (Pfeffer & Philp 2014) . One of the first RPE cell lines, which was clonable and did not lose its pigmentation, was derived from chicken embryos (Cahn & Cahn 1966 ). In the 1970s and 1980s, RPE from human donor samples as well as cultured human RPE became available for us in experimental studies (Mannagh et al. 1973; Del Monte & Maumenee 1980) . Another model originated from fetal human RPE (Aronson 1983) . Later, RPE cell lines from other animals have also been introduced (e.g. pig; Akeo et al. 1988) . Nowadays in vitro experiments are mostly performed in ARPE-19 cells. ARPE-19 is a human RPE-cell line obtained from a 19-year old male donor. The cell line is spontaneously immortal, forms polarized monolayers in culture and displays similar physiological properties as found in RPE cells in vivo (Dunn et al. 1996) . Thus, ARPE-19 cells share a similar efflux protein profile with primary RPE cells (Mannermaa et al. 2009 ). Recently, the use of human stem cell-derived RPE cells have been introduced into in vitro studies. These cells share a similar efflux protein profile to ARPE-19, for example, this makes them suitable for drug research (Juuti-Uusitalo et al. 2012; Sorkio et al. 2014) .
There are also animal models of AMD that mimic some of the pathological features observed in AMD (Fig. 6 ), but none of them capture all of the features of the disease (Pennesi et al. 2012) . As inflammation and the complement system play a major role in AMD, several mouse lines have been developed with genetic alterations in their complement factor pathway. These include mice lacking complement factor H or overexpressing C3, which both show degenerative changes, alterations in the outer segment (e.g. loss of the segment) and problems with visual functions (Coffey et al. 2007; Cashman et al. 2011 ). Other models include chemokine receptor knock-outs (Ambati et al. 2003) and oxidative damage models (Imamura et al. 2006 ). Both models exhibit AMD-like changes, the first with a deficiency in chemoattractant protein or its receptor ultimately leading to impaired macrophage recruitment and the latter with a deficiency in copper-zinc-superoxide dismutase leading to excess oxidative stress.
Mice fed with high-fat diets as well as high glycemic diets show age-related lesions earlier than low-intake controls (Cousins et al. 2002; Weikel et al. 2012) . For example, ApoE4 transgenic mice provided with a high-fat diet displayed drusen like deposits (Ramkumar et al. 2010) . In addition to rodents, nonhuman primates have also been used to model AMD, notably older rhesus macaque monkeys (Bellhorn et al. 1981) . For example, more than half of aged rhesus monkeys have drusen (Gouras et al. 2008) . It has been shown that rhesus monkeys and humans share similar genetic polymorphisms [HTRA1 (high-temperature requirement factor A1) and ARMS2 (age-related maculopathy susceptibility 2)] indicating that they carry similar genetic risk factors (Francis et al. 2008) .
Proteostasis in the development of AMD
Age-related macular degeneration (AMD) pathophysiology consists of oxidative stress, protein aggregation and inflammation. Overall, every cell is constantly degrading and resynthesizing proteins in order to maintain homeostasis. The process of controlling protein has been termed proteostasis (Dokladny et al. 2015) .
Heat-shock proteins in protein folding
If a protein is damaged (e.g. inappropriate aggregation) or misfolded, the cell's primary response is to repair the protein through refolding. This is mediated by heat shock proteins (Hsps; Hartl et al. 2011 ). The Hsps are subdivided into several families according to their molecular size, function and structure (Kaarniranta et al. 2009b) . Hsp70 is the most highly conserved and ubiquitously expressed of this family (Dokladny et al. 2015) . It is involved in the folding of newly synthesized proteins as well as in post-translational folding, in translocation across membranes, and in the above-mentioned refolding process (De Los Rios et al. 2006; Piri et al. 2016) . Interestingly, if the Hsp system is inhibited in RPE cells, the aggregates formed are cleared nevertheless ). This confirms the presence of parallel clearance systems. In addition, the heat shock and lysosome-dependent protein degradation interact with each other. For example, endoplasmic reticulum stress leads to an increase in autophagy related apoptosis (Qin et al. 2010) . Moreover, the overexpression of Hsp70 inhibits autophagy (Dokladny et al. 2013) . Autophagy only exists in eukaryotic cells, whereas the Hsp chaperone system is featured in both prokaryotes and eukaryotes (Dokladny et al. 2015) . Heat shock protein (Hsp) levels are elevated in response to cell stress, such as exposure to excess heat, cold, possible toxins, mechanical damage and oxidation. Increased levels of Hsps have also been detected in AMD, evidence of the involvement of cellular stress (Kaarniranta et al. 2009b) . Because lipofuscin accumulation has adverse effects in lysosomal function, the Hsp system, especially Hsp70, is an important protective factor in RPE homeostasis (Holz et al. 1999; Bergmann et al. 2004; Kaarniranta et al. 2005 Kaarniranta et al. , 2009b Ryh€ anen et al. 2009 ).
Proteasomes and RPE
Normal structure and function of proteins are essential for RPE health. Damaged proteins are degraded by the lysosomal pathway, such as autophagy, if the initial repair attempt fails. If a protein has not been successfully repaired by molecular chaperones, it is tagged with a small polypeptide called ubiquitin and forwarded to the Ubiquitin-Proteasome degradation pathway (Ding & Yin 2008; Kaarniranta et al. 2009b) . Usually more than one ubiquitin is conjugated and a polyubiquitin chain is formed enabling efficient targeting to the proteasome (Howes et al. 2004 ). The eukaryotic proteasome is a multicatalytic proteolytic complex present in cytosol, nucleus and microsomes, and it accounts for 1% of all cytosolic proteins (Tanaka et al. 1986 ). The proteasome recognizes and selectively degrades oxidatively damaged and ubiquitinated proteins. It is also involved in part of cell-cycle regulation and synaptic plasticity as well as in signal transduction, especially in the activation and inhibition of nuclear factor kappaB (Ferrington & Gregerson 2012) .
The UPP is a vital cellular system in removing damaged proteins caused by oxidative stress (Pickart 2001; Goettsch & Bayer 2002) . UPP and lysosomal proteolysis (LPP) usually work independently from each other and have different substrate specificities (Shang & Taylor 2012) . In general, short lived regulatory proteins and soluble abnormal, denatured or otherwise damaged proteins are targeted to UPP whereas proteins associated with membranes or organelles are targeted to LPP (Ravid & Hochstrasser 2008; Korolchuk et al. 2009a,b; Ciechanover 2012) .
As recently demonstrated by our group ), proteasome inhibition in RPE cells causes accumulation of ubiquitinated proteins, which are cleared by autophagocytosis. This implies that the dysfunction of protein degradation has a role in the pathogenesis of AMD (Ferrington et al. 2016) .
Autophagic clearance in RPE
Protein aggregation has a role in AMD pathophysiology. The RPE is constantly combatting this process by activating its chaperones as well as its disposal systems i.e. UPP and LPP. Autophagocytosis, literally meaning 'self-eating', is a basic cellular lysosomal clearance system. This process was first discovered in the 1960s (Arstila & Trump 1969) but its role in cellular pathology was not understood until recently. Autophagy has a key role in maintaining cellular homeostasis (Frost et al. 2014) . Since it clears aged and aggregated proteins, lipid-droplets and organelles from the cytoplasm of all eukaryotic cells . Three different autophagic routes have been discovered: (i) macroautophagy (hereafter called autophagy), (ii) microautophagy and (iii) chaperonemediated autophagy (Mizushima et al. 2008) . Microautophagy, in which small particles are transported directly to the lysosome, is not common in mammalian cells but does occur in plants and fungi (Ahlberg et al. 1982; van Doorn & Papini 2013 ). The autophagic process begins with the formation of phagophores (Fig. 7) . These phagophores then encircle a portion of cytosol and form a distinctive double-membrane autophagosome. Lastly, the autophagosomes fuse with lysosomes and the contained waste is degraded by lysosomal enzymes ). This process is regulated by over 30 autophagy-related proteins (Blasiak et al. 2014 ). There are two important regulators i.e. AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR), the first being a master promoter and the latter an inhibitor (Kim et al. 2011) . AMPK can be activated by the use of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). Interestingly, a recent study revealed that a commercial supplement containing resveratrol was capable of inducing autophagy in ARPE19 cells (Koskela et al. 2016) . This happens by a direct inhibition of mTOR (Park et al. 2016) .
Recently, in AMD donor samples, upregulation of autophagic markers (Atg12-Atg5 and LC3B) was observed along with a decrease in lysosomal activity and mitochondrial damage (Wang et al. 2009c) . Furthermore, if lysosomal activity is repressed, autophagic clearance does not function properly in RPE cells ). Increased lipofuscinogenesis is attributable to the reduced autophagy activity in RPE cells (Krohne et al. 2010c ). Higher levels of lysosomal activity have been observed in the macular area; this would explain why dysfunction of autophagy would exert the most damage in the macula and has been proposed as a reason why AMD affects mostly the macular area of the retina (Boulton et al. 1994; Strauss 2005) . Lipofuscinogenesis, the decrease in lysosomal activity, mitochondrial damage and the vulnerability to oxidative stress all have an association with autophagy (Mitter et al. 2012) by affecting the autophagic flux [i.e. the whole process of autophagy including up-and downregulation (Zhang et al. 2013) ]. As the decrease in autophagic flux can exert and effect on RPE homeostasis, dysfunction of autophagy has been postulated to play a major role in the development of AMD, and for this reason, autophagy can be a potential therapeutic target in the battle against AMD .
Ubiquitin in the regulation of proteostasis. Ubiquitin, a small protein of 8.5 kDa, was first documented in 1975 (Goldstein et al. 1975 ). In the 1980s, it was discovered to be a regulator of protein degradation (Hershko et al. 1980 ). The attachment of ubiquitin, or ubiquitination, may activate or inhibit enzymes and other cellular processes. It has been shown to take a part in the regulation of endocytosis, cell cycle, signal transduction, gene regulation and DNA repair (Welchman et al. 2005; Kirkin & Dikic 2007; Jung et al. 2009 ). Fig. 7 . Autophagocytosis. The process of autophagy begins when it is induced by a phagophore. Induction has several promoters (+) and inhibitors (À), e.g. the downregulation of mTOR (a cellular regulator for growth) induces autophagy. Next, the phagophore elongates and finally matures. Then, the formed mature autophagosome fuses with a lysosome which permits to the degradation of engulfed waste.
Protein degradation begins by ubiquitination of the harmful substrate which is then forwarded either to UPP or targeted for degradation by lysosomal proteolytic pathway, such as autophagy. SQSTM1/p62 (discussed later) works as a shuttling factor in this process. LC3 (Microtubule-associated protein 1A/1B-light chain 3), is 17 kDa protein mediating the interaction between cytoskeletal components and microtubules (Tanida et al. 2008 ). In the absence of LC3, the ubiquitin labeled proteins are targeted to UPP and in the presence of LC3, they are subjected to autophagocytic degradation ( Fig. 8 ; Ichimura et al. 2008) . Inhibition of the UPP increases p62-mediated autophagy (Viiri et al. 2010) . Similarly, to the situation with p62, ubiquitin tends to accumulate and form aggregates if there is a dysfunction of autophagy (Knaevelsrud & Simonsen 2010; Rogov et al. 2014 ).
HuR regulates Hsp70 response. The ELAV1/HuR protein is a post-transcriptional gene expression regulator in eukaryotic cells (Zucal et al. 2015) . The ELAV family of proteins have a distinctive role in various pathological processes including cancers and in inflammatory diseases. This is mainly due to their above-mentioned regulatory role in gene expression. For instance, HuR directly binds to Hsp70 mRNA, and the serine/threonine residues on HuR are then phosphorylated leading to post-transcriptional regulation of Hsp70 (Amadio et al. 2008) . HuR promotes inflammation by interacting with the encoding of pro-inflammatory proteins and its levels haven found to be elevated in various cancers, such as colon, brain and breast cancers. It has been proposed as a marker for these cancers, but clinical applications are absent at the moment (Srikantan & Gorospe 2012) . Notably, ELAV proteins derangements seem to have a role in neurodegenerative diseases, such as AD. HuR levels in the AD hippocampi are decreased whereas beta-amyloid levels are increased (Amadio et al. 2009 ). The dysfunction of the aforementioned HuR-Hsp interaction might be a contributor to these stressful conditions (Amadio et al. 2008 ).
SQSTM1/p62 as a shuttling protein between proteasomes and autophagy.
SQSTM1/p62 (hereafter abbreviated to p62) is a stress-induced protein with a size of 61 kDa. It has a role in amino acid sensing as well as in the oxidative stress response as a signaling hub; it also functions as an autophagy receptor for ubiquitinated cargos (Katsuragi et al. 2015) . It was first characterized in polyubiquitinated aggregates in cells which had been subjected to proteasomal depletion (Kuusisto et al. 2001b ) and later found to be expressed in numerous neurodegenerative diseases, most notably AD . p62 activates protein Nrf2 (nuclear factor E2-related factor 2), which controls the expression levels of several antioxidant proteins and thus protects against oxidative damage . When damaged or otherwise misfolded proteins have been polyubiquitinated, p62 shuttles them to the autophagosomes. LC3 presents the autophagosome membrane and after induced binding the aggregates are degraded ( Fig. 8 ; Pankiv et al. 2010 ). As p62 is itself degraded by autophagy, any dysfunction of autophagy might lead to p62 accumulation and subsequently to the formation of aggregates (Komatsu & Ichimura 2010) . Hence, p62 can be used as an autophagy marker, since the transcription of p62 is upregulated during impaired autophagy (Klionsky et al. 2016) . Inhibition of p62 transcription blocks proteasomal sequestration of ubiquitinated proteins and blocks the enlargement of inclusions. Therefore, p62 plays a vital role in the defense of cells from the toxicity of misfolded proteins by augmenting aggregate formation (Nakaso et al. 2004; Paine et al. 2005 ).
Beclin-1 as an inductor of autophagy.
Beclin-1 is a 52 kDa protein that is essential for initiation of autophagocytic process (Salminen et al. 2013; Mei et al. 2014) by Beclin-1 promoted vesicle nucleation (Suzuki et al. 2001) . It was first discovered as a protein, which interacts with Bcl-2, a cellular antiapoptotic gene (Liang et al. 1998) . Beclin-1 is crucial for neuronal survival and it is widely expressed in the nervous system (O'Brien et al. 2015) . A Beclin-1 deficiency has worsened amyloid B induced pathology in a mouse model of AD by decreasing autophagy, resulting in increased accumulation of amyloid B. In this model, representing heterozygous deletion of Beclin-1, the administration of a viral vector capable of triggering Beclin-1 overexpression, was able to reduce the amyloid B accumulation (Pickford et al. 2008 ). There are indications that the amyloid B may be generated in autophagic vacuoles (Yu et al. 2004) . It has been reported that the expression of Beclin-1 is reduced in patients with Alzheimer's disease (Pickford et al. 2008) and its dysfunction has a role in the pathogenesis of AD by affecting neuronal autophagy (Salminen et al. 2013 ). In addition, pre-exposure of RPE cells to AE2, a component of lipofuscin, triggered the induction of autophagosomes and increased Beclin-1 expression . Since AD and AMD share similar pathophysiological backgrounds, it is possible that a dysfunction of Beclin has a role in the pathogenesis of AMD.
Collagen XVIII and endostatin
As stated, AMD and AD share many pathophysiological features. The expression of collagen XVIII has been demonstrated in the plaques of AD patients (van Horssen et al. 2002) . Collagen XVIII belongs to a group of proteins, which make up a major proportion of the components of basement membranes (Ortega & Werb 2002) . Interestingly, collagen XVIII also has a role in the development of the brain and eyes by ensuring the correct function of basement membranes (Fukai et al. 2002; Lakshmanachetty & Koster 2016) . Collagen XVIII is expressed in BMs throughout the body (Muragaki et al. 1995) and thus it is present nearly in every part of the human eye (Bowman's membrane, the lens capsule, the trabecular network and in all the endothelial and epithelial basal membranes in both anterior and posterior segments of the eye; Ohlmann et al. 2005) .
Mutations (mostly nonsense mutations) in the Col18a1 gene lead to Knobloch syndrome. This is an autosomal recessively inherited disease (Serti e et al. 2000) . The disease was first discovered in 1971 (Knobloch and Layer) and it is characterized by ocular manifestations and in some of the cases also occipital skull abnormalities are present. Ocular manifestations include severe myopia [when spherical equivalent refraction is <À6.00 D (Koh et al. 2016) ]; subluxation of the lens; vitreoretinal degeneration which tends to lead to retinal detachment; and cataracts with an early onset (Khan et al. 2012 ). The reported skull abnormalities include encephalocele, bone defects or cutis aplasia (Sniderman et al. 2000) . Since the first report, at least 85 cases have been identified (Caglayan et al. 2014) . Interestingly, mice with collagen 18 depletion have been observed to display numerous ocular abnormalities and age-dependent loss of vision with accumulation of sub-RPE deposits (Fukai et al. 2002; Marneros et al. 2004) . Retinal neovascularization has also been observed (Hurskainen et al. 2005) .
Another interesting feature of collagen XVIII is its C-terminal domain. This domain is called endostatin and it is produced via proteolytic cleavage (O'Reilly et al. 1997) . It has both antiangiogenic and anti-proliferative effects (Behl & Kotwani 2015) and can inhibit at least 65 different types of tumors (Folkman 2006) . Endostatin inhibits the migration and proliferation of new endothelial cells, which at least to some extent, explains its anti-angiogenic effects (Yamaguchi et al. 1999 ). An interesting finding is that endostatin can also induce autophagy by increasing Beclin-1 levels (Nguyen et al. 2009 ). It has been shown to be localized in the structures surrounding the vitreous and anterior chamber, which are normally avascular structures allowing light to pass undisturbed into the neural retina. The distribution of endostatin might indicate a possible role for these structures to guard against vascularization (Ohlmann et al. 2005) . Endostatin is currently in phase II clinical trials as an angiogenesis inhibitor and it has been proposed to be used also in the treatment of diabetic retinopathy (Behl & Kotwani 2015) .
Aims of Study
The general aim of the study was to evaluate the role of protein aggregation, especially dysfunction of autophagy in the pathogenesis of age-related macular degeneration.
The specific aims are: 1 To evaluate the presence of protein degradation markers ubiquitin, LC3 and SQSTM1/p62 in ARPE19-cells and in the RPE of human cadaver AMD samples. (Publication I) 2 To examine the connection between the proteostasis regulator Hsp70 and the autophagic clearance system. (Publication II) 3 To determine whether the current standard of care for wet AMD (intravitreal aVEGF therapy with bevacizumab) has an effect on the autophagy clearance of RPE cells. 
Introduction
Age-related macular degeneration (AMD) is the most common eye disease leading to visual impairment in the elderly in the developed countries ). The disease affects the central retina called the macula, the area that is responsible for the most important sharp and colour vision (Kaarniranta et al. 2011) . AMD is associated with aging, hereditary background, smoking, hypertension, hypercholesterolemia, arteriosclerosis, obesity and unhealthy diet. In global terms, 50 million people are affected by AMD with one-third of them suffering severe visual loss (Geh et al. 2006; Gordois et al. 2012) . It is estimated that the number of AMD patients will triple during the next decades due to increased numbers of aged people (Friedman et al. 2004 ).
Primarily AMD is characterized by degeneration of the macular retinal pigment epithelial (RPE) cells that secondarily leads to cell death of photoreceptors (rods and cones) and visual loss (Kaarniranta et al. 2009b ). Age-related macular degeneration has a progressive character and may develop into either a dry (non-exudative) or wet (exudative) form (de Jong 2006; Jager et al. 2008) . Neovascularization, sprouting from the choriocapillaries into the retina, is one of the clinical hallmarks of wet AMD. The dry form of the disease is more prevalent and it accounts for as many as 90% of all cases. At present, no effective cure is available for dry AMD, although anti-oxidants and omega-fatty acids have been shown to have preventive properties in certain AMD patient groups Sin et al. 2012) . In wet AMD, monthly applications of intravitreal injections of anti-VEGF antibodies have been used to suppress the activity of neovascularization (The CATT Research Group 2011) .
Age-related macular degeneration (AMD) pathogenesis involves chronic oxidative stress, increased accumulation of lipofuscin in the lysosomes of RPE cells, as well as extracellular drusen formation and presence of chronic inflammation (Finnemann et al. 2002; Terman et al. 2010; Kaarniranta et al. 2011 ). The ability to prevent the accumulation of cytotoxic protein aggregates via autophagy may be decreased in aged post mitotic RPE cells leading to degenerative changes.
Autophagy is basic catabolic mechanism which 'self eats' cellular components that are unnecessary or dysfunctional to the cell (Yang & Klionsky 2010a) . Autophagy comprises three intracellular pathways in eukaryotic cells, which are macroautophagy (hereafter referred to as autophagy), microautophagy and chaperone-mediated autophagy (Mizushima & Komatsu 2011) . Apart from its important role in cellular homeostasis, autophagy is also triggered as an adaptive response during AMD-associated stress conditions (Kaarniranta et al. 2009b; Yang & Klionsky 2010b; Kaarniranta et al. 2011; Mizushima & Komatsu 2011) . Autophagy process begins with the formation of isolation membranes called phagophores; these latter then become elongated and surround portions of cytoplasm containing oligomeric protein complexes and organelles to form mature double membrane autophagosomes. The autophagosomes fuse with the lysosomes and their content is then degraded by lysosomal enzymes. Failure of autophagy in aged postmitotic cells, including RPE cells, can result in accumulation of aggregate-prone proteins, cellular degeneration and finally cell death (Kaarniranta et al. 2009b) .
SQSTM1/p62 (Sequestosome 1) is the best-characterized and ubiquitously expressed autophagy receptor that connects proteasomal clearance with lysosomes (Bjørkøy et al. 2005; Komatsu et al. 2007; Korolchuk et al. 2009b; Pankiv et al. 2010; Viiri et al. 2010) . Alleviation of autophagy is usually accompanied by an accumulation of SQSTM1/p62 mostly in large perinuclear aggregates or inclusion bodies which are also positive for ubiquitin, as reported in numerous neurodegenerative diseases (Kuusisto et al. 2001a (Kuusisto et al. , 2002 Zatloukal et al. 2002; Braak et al. 2011; Geetha et al. 2012; ).
The evidence indicates that SQSTM1/p62 is a stress response gene strongly induced at mRNA and protein levels by the exposure to various oxidative stimuli and proteasomal inhibitors (Ishii et al. 1997; Kuusisto et al. 2001b; Nagaoka et al. 2004; Jain et al. 2010) .
One of the most important posttranscriptional mechanisms involves ELAVL1/HuR (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) protein, acting mainly as a positive regulator of gene expression by binding to and increasing the stability and/or translation of specific mRNAs whose corresponding proteins are fundamental for key cellular functions. It is noteworthy that ELAVL1/ HuR, and in general ELAV family, participates in various physio-pathological processes where oxidation and stress play a primary role (Amadio et al. 2009; Pascale & Govoni 2012; Srikantan & Gorospe 2012) . One of the main aims of our study was to investigate whether SQSTM1/p62 mRNA would be a target of ELAVL1/HuR protein, and whether the binding between ELAVL1/HuR protein and SQSTM1/p62 transcript exists in human RPE cells. We also investigated how proteasomal and autophagy modulation affects SQSTM1/p62 and ELAVL1/HuR expression. Moreover, their presence in drusen rich human cadaver AMD samples was studied.
Materials and methods

Ethics statement
The study was approved by the Ethics Committee of the Freiburg University Hospital, the University of Debrecen and the tenets of the Declaration of Helsinki were followed for human material. Participants provided their written informed consent for the human material in this study.
Cell culture and treatments ARPE-19 human RPE cells were obtained from the American Type Culture Collection (ATCC). The cells were grown to confluence in a humidified 10% CO2 atmosphere at 37°C in Dulbecco's MEM/Nut MIX F-12 (1:1) medium (Life Technologies, 21331, Carlsbad, California, The United States of America) containing 10% inactivated fetal bovine serum (Hyclone, SV30160-03, Fisher Scientific, Hampton, New Hampshire, The United States of America), 100 units/ml penicillin and 100 lg/ml streptomycin (Lonza, DE17-602E, Basel, Switzerland) and 2 mM L-glutamine (Lonza, BE17-605E, Basel, Switzerland). In proteasome experiments, the cells were exposed to 5 lM MG-132 proteasome inhibitor (Calbiochem, 474790, Merck KGaA, Darmstadt, Germany) for 0.5, 3, 12 and 24 hr. The cells were exposed to 50 nM bafilomycin A1 (Sigma, B1793, Saint Louis, Missouri, The United States of America) for 24 h. Additionally, the cells were treated with the AMPK (AMP-activated protein kinase) activator, AICAR 2 mM (5-aminoimidazole-4-carboxamide ribonucleoside; Toronto Research Chemical, A611700, Toronto, Ontario, Canada) for 0.5, 3, 12 and 24 hr. Furthermore, the autophagy was induced with starvation by culturing cells in fetal bovine serum free medium for 0.5, 3, 12 and 24 hr.
Cellular fractionation and western blotting
The nuclear extract kit (40010) from Active motif was used for the preparation of nuclear and cytoplasmic extracts from exposed ARPE-19 cells. Gurskaya et al. 2006) . Ligated (T4 DNA Ligase, Roche, 10481220001) DNA, forming a fusion gene of Dendra2 and human MAP1LC3A/LC3 was transfected into competent DH5a E. coli cells, which were prepared using the protocol of Inoue and others and then cultured and purified (Inoue et al. 1990; Sambrook et al. 1990 ). The integrity of the construct, named hereafter as pDendra2-hLC3 (MAP1LC3A/LC3), was determined initially by restriction endonuclease digestion analysis and finally sequencing of both the junction sites and the entire inserted MAP1LC3A/LC3 ORF. Human Sequestosome 1, SQSTM1 (p62), NCBI gene bank no. NM_003900) was similarly inserted into the pDendra2 vector. The ORF insert was initially purchased from RZPD (Deutsches Ressourcenzentrum f€ ur Genomforschung, IRAUp969A0698D). The insert was amplified with the following primers: sense 5 0 -ATA CTC GAG at ATG GCG TCG CTC ACC; reverse 5 0 -TAT AAG CTT a TCA CAA CGG CGG GGG ATG. The restriction sites for XhoI and HindIII are shown in italics and the translation initiation and termination sites are in boldface. The additional bases enabling in-frame cloning are in minuscules. The final plasmid was named as pDendra2-hp62 (SQSTM1/p62).
Transfections and Confocal Imaging of pDendra2-hLC3 (MAP1LC3A/LC3) and pDendra2-hp62 (SQSTM1/p62) ARPE-19 cells were cultured in 8-well plates (l-Slide, ibiTreat, tissue culture treated, Ibidi, 80826) in a volume of 200 ll to a subconfluent density. In all transfection experiments, ExGen 500 in vitro Transfection Reagent (MBI Fermentas, R0511, Thermo Fischer Scientific, Waltham, Massachusetts, The United States of America) was used and its protocol followed. The DNA content was 500 ng per single well and the transfection treatment lasted for 24 hr. Chemical treatments with 5 lM MG-132 and/or 2 lM AICAR followed for 24 hr in fresh medium.
Before the microscopic evaluation, the medium was always changed to a fresh medium without treatment. The nuclei were stained with DRAG5 TM (Biostatus, DR50050, Shepshed, Leicestershire, The United Kingdom), diluted to 1/1000 in phosphate-buffered saline. The fluorescent images were obtained with a Zeiss Axio Observer inverted microscope (63 9 NA 1.4 oil objective) equipped with Zeiss LSM 700 confocal module (Carl Zeiss Microimaging, Oberkochen, Germany). The change in the Dendra2 color from green to red was achieved by treatment of the cells with 405 nm UV-light (Inoue et al. 1990 ). In the live cell imaging, a Zeiss XL-LSM S1 incubator with temperature and CO2 control was utilized. ZEN 2009 software (Carl Zeiss, Oberkochen, Germany) was used for image processing.
Attenuation of the ELAVL1/HuR gene expression by RNA interference
A control siRNA (NEG-siRNA) having no known homology with any gene (Ambion, AM4641, Thermo Fisher Scientific, Waltham, Massachusetts, The United States of America) and siRNA designed for the human ELAVL1/HuR gene (Ambion, s4610) were used. The ELAVL1/HuR siRNA has sense sequence GCG UUU AUC CGG UUU GAC ATT, and the binding site is at the bases 615-633 of the human ELAVL1/HuR gene (NCBI gene bank no. NM_001419) in exon 2, near to the 5 0 -end of the coding region. siRNAs were transfected into ARPE-19 cells using siPORT TM Amine transfection reagent (Ambion, AM4502) following the manufacturer's instructions. Cells were grown as described above.
The concentration of siRNAs in cell cultures was 30 nM and duration of siRNA treatment was held for 24 hr, followed by MG-132 treatment (5 lM) for 24 hr. The decrease of ELAVL1/ HuR expression was monitored using real time quantitative RT-PCR and western blotting.
Immunoprecipitation followed by RNA extraction
Immunoprecipitation on RPE cytoplasmic fractions was performed according to a previously published protocol with minor modifications (Tenenbaum et al. 2002) . Briefly, immunoprecipitation was performed at room temperature for 2 hr using 1 lg of anti-Hu antibody per 50 lg of proteins diluted with an immunoprecipitation buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 0.05% Igepal, 20 mM EDTA, 100 mM DTT, protease inhibitor cocktail and an RNase inhibitor) in the presence of 50 ll of protein A/G plus agarose (Santa Cruz Biotech, sc-2003) . The samples were finally subjected to RNA extraction. The negative control was obtained under the same conditions, but in the presence of an irrelevant antibody with the same isotype of the specific immunoprecipitating antibody. One hundred microliters of the immunoprecipitation mix were immediately collected from each sample and used as 'input signals' to normalize the RT-PCR data.
Real-time Quantitative RT-PCR
RNA was extracted from total homogenates, immunoprecipitated pellets and relative 'input signals' by using RNeasy MicroPlus Kit (Qiagen, 74034, Hilden, Germany). The reverse transcription was performed following standard procedures. PCR amplifications were carried out using the Lightcycler instrument (Roche Molecular Biochemicals, Basel, Switzerland) in the presence of QuantiTect SYBR Green PCR mix (Qiagen, 204143) with primers designed by using the PRIMER3 software (http://www-ge nome.wi.mit.edu/cgi-bin/primer/prime r3_www.cgi). Primer sequences were as follows: ELAVL1/HuR, 5
0 (downstream). The RPL6 mRNA was chosen as the reference on which the ELAVL1/ HuR and SQSTM1/p62 values were normalized because it remained relatively stable during all the treatments and it does not bear adenine/uracil-rich elements (ARE) sequences (not shown).
In the statistical analysis the GraphPad Instat statistical package (version 3.05; GraphPad Software, San Diego, CA, USA) was used. The data were subjected to analysis of variance (ANOVA) followed, when significant, by an appropriate test, in function of the number of samples. Differences were considered statistically significant when p values <0.05.
Preparation of the vector expressing HuR cMyc-His-tagged protein ELAVL1/HuR cDNA (NM 001419) was obtained and amplified from MCF7-cells retro-transcribed RNA and inserted into the pCMV6-AC-Myc-His PrecisionShuttle vector (PS100006; Origene Technologies) by using the forward (5 0 -GCC GCGATCGC CATGTCTA-ATGGTTATGA-3 0 ) and reverse (5 0 -CGT ACGCGT TTTGTGGGACTTG-TTGG-3 0 ) primers containing the SgfI and the MluI restriction sites (in italics), respectively. The full-length open reading frame, with the Myc-His tag-encoding sequence located at the 3 0 -end, was confirmed by sequencing.
Recombinant vector pCMV6-HuR (ELAVL1/HuR) was transfected (3 mg per 10 cm tissue culture dish) in HEK293T cells by using Lipofectamine Ò 2000 transfection reagent (Life Technologies, 11668019) according to the manufacturer's protocol. Cells were harvested 48 hr after transfection and sonicated (3 9 15 seconds, paused by 1 min) with 75 of amplitude at 4°C, in binding buffer (20 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazole, pH 7.4) supplemented with Protease Inhibitor Cocktail (Sigma, P8340). Recombinant ELAVL1/HuR HuR-Myc-His proteins were purified by one-step affinity chromatography on HisTrap HP columns (GE Healthcare, 17-5247-01, Little Chalfont, The United Kingdom) following the recommended protocol and were eluted with 20 mM NaH2PO4, 0.5 M NaCl, 50 mM glycine, 300 mM imidazole, 10% glycerol, pH 7.5.
Amplified luminescent proximity homogenous assay
Amplified
Luminescent Proximity Homogenous Assay (ALPHA) was applied to study the interaction between recombinant ELAVL1/HuR and two specific ARE-bearing RNA oligos designed from 3 0 UTRs of TNFalpha and SQSTM1/p62. Biotinylated singlestranded TNFalpha (40) 
0 ) RNAs were purchased from Eurofins MWG Operon and recombinant ELAVL1/ HuR HuR-MYC/DDK protein (TP301562) was purified from HEK293T cells transiently transfected with pCMV6-ELAVL1/HuR. The assays were performed in 384-well white OptiPlates (PerkinElmer, 6007299, Waltham, Massachusetts, The United States of America) using a final volume of 25 ll and optimized by titrating both interacting partners (in order to determine the optimal protein: RNA ratio). Values out of the 'hooking zone', where quenching of the signal was due to an excess of the binding partner, were used to determine the optimal concentrations of RNA-oligos and proteins. All reagents were tested in the nanomolar range using the Alpha Screen c-Myc detection kit (Perkin Elmer, 6760611C) and reacted in a buffer containing 25 mM HEPES (pH 7.4), 100 mM NaCl, and 0.1% bovine serum albumin (BSA). Briefly, recombinant ELAVL1/HuR protein (range 0.1-300 nM tested, data not shown) was incubated with a biotinylated single-stranded RNA (range 0.1-300 nM) and with anti-cMyc Acceptor beads (20 lg/ml final concentration) and, subsequently, the reaction was placed in the dark at room temperature for 30 min. The incubation in the same conditions was extended to 90 min after addition of streptavidin Donor beads (20 lg/ml final concentration). Specific interactions were quantified on a PerkinElmer Enspire plate reader by subtracting the signal of the background (non-specific binding). Dissociation constants (K d ) for TNFalpha (0.087 AE 0.021), and SQSTM1/p62 (0.207 AE 0.024) were determined from nonlinear regression fits of the data according to a 1-site binding model in GraphPad Prism Ò , version 5.0 (GraphPad Software, Inc.).
Transmission electron microscopy
For transmission electron microscopy, the cells were treated with 5 lM MG-132 and/or 2 mM AICAR for 3, 12 and 24 hr. Cell culture samples were prefixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer pH 7.4 for 2 hr at RT. After 15 min washing in 0.1 M phosphate buffer, the samples were postfixed in 1% osmium tetroxide and 0.1 M phosphate buffer for 1 hr, and again washed with phosphate buffer for 15 min prior to standard ethanol dehydration. Subsequently, the samples were infiltrated and embedded in LX-112 resin. Polymerization was carried out at 37°C for 24 hr and at 60°C for 48 hr. The sections were examined with a JEM-2100F transmission electron microscope (Jeol) at 200 kV.
Aggregates and autophagic vesicles were manually counted. Eight cells were randomly selected from each group for counting aggregates and six cells for autophagic vesicles. Statistical analysis was performed using SPSS (v. 19; IBM, SPSS Inc). The significance of differences between control and treated groups was analyzed with Mann-Whitney U-test. p-values <0.05 were considered significant.
Cytotoxicity assay
Cytotoxicity to the AICAR and other treatments was monitored by measuring the amount of lactate dehydrogenase (LDH) enzyme from the culture medium samples. The Cyto-Tox 96 Non-Radioactive Cytotoxicity Assay kit (Promega, G1781, Madison, Wisconsin, The United States of America) was used for detection according to the instructions of the manufacturer. Absorbance values after the colorimetric reaction were measured at a wavelength of 490 nm with a reference wavelength of 655 nm using a BIO-RAD Model 550 microplate reader. Statistical analysis was performed using SPSS program (v. 19; IBM SPSS Inc, Armonk, New York, The United States of America). The significance of differences between control and treated groups was analyzed with Mann-Whitney U-test (n = 6). p-values <0.05 were considered significant.
Assay for cell death analysis
Cell death was assessed by the Annexin-V-fluorescein isothiocyanate. We used the Apoptosis Detection Kit (MBL, BV-K 101-4) according to the manufacturer's recommendations; the proportion of stained Annexin-V + and Annexin-V + /Propidium iodide + cells was determined by fluorescence activated cell sorter (FACS) analysis on FACSCalibur flow cytometer (BD Biosciences Immunocytometry Systems, San Jose, CA, USA) and data were analyzed using WinMDI freeware (Joseph Trotter, La Jolla).
Immunohistochemistry
Patients with dry AMD rich with drusen had been diagnosed based on biomicroscopy and fundus photographs in the Department of Ophthalmology of Freiburg University Hospital. The study was approved by the Ethics Committee of the Freiburg University Hospital and the tenets of the Declaration of Helsinki were followed. Eyes from two age-matched patients without clinically diagnosed AMD were used as a control; one eye was provided by the Department of Ophthalmology of Freiburg University Hospital and the other one by the Department of Ophthalmology of University of Debrecen. In both cases, the tenets of the Declaration of Helsinki were followed. Enucleated eyes from cadaver human samples were embedded in paraffin according to a routine protocol and horizontal sections (5 lm) of four eyes were immunostained for SQSTM1/p62, ubiquitin (Ub) and ELAVL1/HuR. The extent of immunopositivity in the retinal pigment epithelial cells was evaluated microscopically (no staining or positive staining) by selecting 5 mm long areas of the foveomacular, perimacular and peripheral regions. All the horizontal sections were, based on the histological anatomy, from the corneal level. Foveomacular, perimacular and peripheric areas were analysed as a pack from the same horizontal section. The stainings were done with Thermo Scientific's UltraVision LP Detection System AP Polymer & Fast Red Chromogen (TL-015-AF) kit according to the manufacturer's instructions. The antibodies used were mouse monoclonal for SQSTM1/p62 (Santa Cruz, sc-28359), rabbit polyclonal for ubiquitin (Dako, Z0458, Santa Clara, California, The United States of America) and the mouse monoclonal for ELAVL1/HuR (Santa Cruz, sc-5261). The dilutions were 1:500, 1:1100 and 1:500 respectively. Human brain with Alzheimer's disease was used as a method control for the stainings (data not shown). After the staining samples were analyzed as described above, using a Zeiss AX10 Imager A2 (Gottingen) light microscope and a Jenoptik ProgRes C5 (Optical Systems, Jena, Germany) digital camera mounted on to the microscope. Photographs were taken with the same camera. The statistical analysis for the results was conducted with a Mann-Whitney test in the SPSS Statistics 17.0 program (IBM SPSS Inc).
Results
AICAR treatment strongly counteracts the MG-132-induced increase of SQSTM1/p62 protein levels in In order to identify the optimal conditions to study the effects on SQSTM1/ p62 protein levels, the ARPE-19 cells were first treated with the proteasome inhibitor MG-132 (5 lM) and/or the autophagy activator, AICAR (2 mM) over a time range (data not shown). Western blotting analysis revealed that a statistically significant change in total SQSTM1/p62 protein levels was detectable only after 24 hr treatments, so this time point was selected for further studies. In particular, as shown in Fig. 9A , the proteasome inhibitor MG-132 significantly increased total SQSTM1/p62 protein levels, while concomitant treatment with MG-132 and AICAR robustly decreased SQSTM1/ p62 protein levels. In contrast, no difference in SQSTM1/p62 protein levels was detected after exposure to AICAR alone (Fig. 9A) . Interestingly, by performing cellular fractionation, we found that in comparison to control cells, MG-132 evoked a significant increase in the SQSTM1/p62 protein levels mainly in the nuclear/perinuclear compartment and also in the cytoplasm (1658%, p < 0.05 and +48%, p < 0.001, respectively; Fig. S1A+ ). Analogously to SQSTM1/p62, MG-132 also significantly increased ELAVL1/ HuR protein levels in the nuclear/perinuclear compartment, in the cytoplasm (+154%, p < 0.001 and +64%, p < 0.01 respectively; Fig S1B) and in the total homogenate (Fig. 9B) . In contrast to SQSTM1/p62, the MG-132-induced increase of ELAVL1/HuR protein was not affected by the concomitant treatment with AICAR, as reported in Fig. 9B , suggesting that ELAVL1/HuR protein is not degraded via autophagy.
To confirm the capability of AICAR to induce autophagy, MAP1LC3A/ LC3-II protein levels were detected after 0.5, 3, 12 and 24 hr by western blotting (Fig. 9C) . Indeed, when cotreated with MG-132, AICAR clearly increased MAP1LC3A/LC3-II protein levels after 0.5 hr, while after 24 hr treatment MAP1LC3A/LC3 lipidation was already over (Fig. 9C ), in accordance with the SQSTM1/p62 levels. We also wanted to compare AICAR response with starvation, a condition that is known as autophagy inducer. As well as for AICAR, starvation-induced autophagy required the presence of the proteasome inhibitor MG-132; conversely to AICAR, starvation-induced autophagy under proteasome inhibition begun later than AICAR (3 hr versus 0.5 hr) in ARPE-19 cells.
It has been documented that SQSTM1/ p62 is oxidative stress-related and ubiquitin-binding protein (Nakaso et al. 2004 ). We here confirmed that 24 hr MG-132 treatment induces the increase of SQSTM1/p62 mRNA expression in the total homogenate of ARPE-19 cells (Fig. S2B) . Then we wanted to determine whether a positive regulation of SQSTM1/p62 expression occurs also at post-transcriptional level in human ARPE-19 cells, following MG-132 treatment.
First, we analyzed the SQSTM1/p62 sequence to identify the cis-acting elements and the corresponding trans-acting factors potentially affecting SQSTM1/ p62 mRNA stability and/or translation. A detailed primary sequence analysis of SQSTM1/p62 revealed the presence of ARE in the 3 0 -untranslated region (3 0 -UTR), three of which (AUUUA) represent the canonical class I sequence recognized by the RNA-binding ELAV proteins. This region was consequently selected to design a probe used in protein-RNA binding AlphaScreen assay, an in vitro technology which can be utilized to evaluate the possible binding between ELAVL1/HuR protein and SQSTM1/ p62 mRNA. An ARE-bearing probe, a portion of TNFa 3 0 UTR, was employed as the positive control of the experiment since it contains well characterized ELAV-target sequences (Schaljo et al. 2009 ).
As shown in Fig. 10A ,B, ELAVL1/ HuR protein physically interacts with the SQSTM1/p62 probe, leading to the formation of a stable protein-RNA probe complex. From saturation binding experiments we calculated the dissociation constants for the two RNA probes. The resulting binding efficiency for the SQSTM1/p62 probe was 8 times weaker than the TNFa probe, as it can be reasonably explained by the presence of four canonical AREs within the TNFa probe compared to the one present in the SQSTM1/p62 probe.
To confirm the finding obtained in the in vitro experiments and to evaluate whether the binding between ELAVL1/ HuR protein and SQSTM1/p62 mRNA exists also in our cell system, we then performed immunoprecipitation coupled with RT-real-time qPCR experiments on control and MG-132 treated cells. It was Fig. 9 . MG-132-induced increase of SQSTM1/p62 but not ELAVL1/HuR protein levels is counteracted by AICAR treatment. Representative western blotting (upper) and densitometric analysis (lower) of SQSTM1/p62 (A), ELAVL1/HuR (B) and MAP1LC3A/LC3-II (C) proteins in the total homogenates of ARPE-19 cells after starvation or/and exposure to AICAR (2 mM) or/and MG-132 (5 lM) for 0.5, 3, 12 and 24 hr. a-Tubulin was used as a loading control. Control cells were exposed only to solvent (DMSO). Results are expressed as means AE SEM. The data were analyzed by ANOVA, followed by Dunnett's Multiple Comparison Test; *p < 0.05, **p < 0.01, control versus treated, n = 7 (SQSTM1/p62 and ELAVL1/HuR), n = 3 (MAP1LC3A/LC3-II).
found that the MG-132-induced upregulation of SQSTM1/p62 mRNA in the cytoplasm of ARPE-19 cells (Fig. 10C ) was accompanied by a parallel increase of the binding between ELAVL1/HuR protein and SQSTM1/ p62 mRNA in the same cellular fraction (Fig. 10D) , indicating that MG-132 treatment induced a positive regulation of SQSTM1/p62 expression that occurred also at the post-transcriptional level via ELAVL1/HuR protein. To further confirm this hypothesis, we silenced ELAVL1/HuR expression in ARPE-19 cells by siRNA technology and then exposed these cells to MG-132 for 24 hr. First, we found that MG-132 treatment strongly up-regulates ELAVL1/HuR mRNA expression in ARPE-19 cells (Fig. S2A) . Conversely, in silenced cells, MG-132 does not affect ELAVL1/HuR mRNA total amount that is indeed comparable to control levels (Fig. S2A) . We then evaluated ELAVL1/HuR protein levels finding that, besides ELAVL1/ HuR mRNA, ELAVL1/HuR-siRNA also counteracted MG-132-induced ELAVL1/HuR protein accumulation (Fig. 11A ). In parallel, we found that, in ELAVL1/HuR-silenced cells, the MG-132 exposure leads to an up-regulation of SQSTM1/p62 mRNA expression to a less extent than in MG-132-treated control cells (Fig. S2B) . Moreover, the MG-132-induced increase of SQSTM1/p62 protein was counteracted in ELAVL1/HuR silenced cells (Fig. 11B) , for the first time suggesting that the positive regulation of SQSTM1/p62 expression, during proteasomal inhibition, requires the specific presence of ELAVL1/HuR protein.
AICAR promotes the complete clearance of MG-132-induced protein aggregates, SQSTM1/MAP1LC3A (p62/LC3) colocalization and autophagy-related gene expression
As shown in Fig. 9A , SQSTM1/p62 protein levels decreased following concomitant treatment with MG-132 and AICAR, subsequently we investigated in more detail the capacity of AICAR to affect protein aggregation which normally occurs under proteasome inhibition in ARPE-19 cells. The cells were thus exposed to AICAR and MG-132 and protein aggregates were examined in a transmission electron microscope. As shown in Fig. 12 , AICAR was able to completely abolish the MG-132-induced protein aggregation after 24 hr treatment. Moreover, there was also observed obvious reduction of aggregates after 3 and 12 hr AICAR-and MG-132-cotreated cells (data not shown). Consistently with Fig. 9 results, the amount of autophagic vesicles increased during first 3 and 12 hr significantly when cells were treated with AICAR together with MG-132 (Fig. 13) . These results show that this concomitant treatment strongly switcheson autophagy at an early time and clearance is already over after 1 day.
Since it is known that SQSTM1/p62 protein contains MAP1LC3A/LC3 interacting domain (Pankiv et al. 2007) we evaluated if SQSTM1/p62 protein would be co-localized with the autophagosome marker MAP1LC3A/ LC3 under different stimuli in ARPE-19 cells. The cells were transfected with pDendra2-hLC3 (MAP1LC3A/LC3) and pDsRed2-hp62 (SQSTM1/p62) plasmids, exposed to AICAR and MG-132 as previously described in the text, and analyzed by live confocal microscopy. Figure 14A illustrates that MAP1LC3A/LC3 and SQSTM1/p62 proteins co-localized after all treatments and that a clear perinuclear accumulation of both proteins could be seen after MG-132-induced proteasome inhibition. In agreement with previous data, the cells treated concomitantly with MG-132 and AICAR exhibited a strong reduction of the perinuclear aggregates containing both MAP1LC3A/LC3 and SQSTM1/p62 proteins (Fig. 14A ). In addition, we noted that MAP1LC3A/LC3 puncta were somewhat larger in AICAR-treated cells than untreated cells. This interesting observation remains still to be studied. It has been previously shown that SQSTM1/p62 protein accumulates in perinuclear aggregates that undergo autophagy clearance (Bjørkøy et al. 2005; Viiri et al. 2010) . According to our unpublished data there are proteins that have reversible binding capacity to perinuclear aggregates. Therefore, we wanted to evaluate whether binding of SQSTM1/p62 to aggregates is reversible or irreversible prior to autophagy. In order to observe whether, under MG-132 stimulus, the increased SQSTM1/ p62 protein levels were accompanied by its intracellular translocation in ARPE-19 cells, the fusion protein plasmid construct pDendra2-hp62 (SQSTM1/ p62) was created and transfected to cells. Confocal microscopy was used for live cell imaging and the movement of SQSTM1/p62 protein was evaluated after photo converting pDendra2-hp62 (SQSTM1/p62; Fig. 14B ). Two areas containing SQSTM1/p62 protein were photoconverted: the intensively aggregated SQSTM1/p62 and the amorphously aggregated SQSTM1/p62. We detected no position changes of SQSTM1/p62 protein from the converted area to other parts of the cell within 1 min, indicating that accumulated SQSTM1/p62 is stationary in ARPE-19 cells treated for 24 h.
AICAR is well-tolerated and prevents cell death in MG-132 long-exposed ARPE-19 cells Next we evaluated how well ARPE-19 cells could tolerate exposure to AICAR. Cellular toxicity was evaluated in two ways after 24 hr exposure to AICAR on its own and/or with the proteasome inhibitor MG-132 by lactate dehydrogenase and Annexin-V assays. AICAR treatment, in the presence or absence of the proteasome inhibitor, did not increase lactate dehydrogenase release as compared to untreated control cells after 24 hr (Fig. S3A) , evidence of the good cellular tolerability towards AICAR. Annexin-V and Propidium Iodide double staining revealed that MG-132 treatment is able to induce apoptosis after prolonged (48 and 72 hr) exposure; in particular, we found that proteasome inhibition clearly induced early and late apoptosis, the latter being more pronounced after 72 hr of treatment (Fig. S3B) . After exposure for both 48 and 72 hr to MG-132, the concomitant presence of AICAR counteracted the apoptotic effects, indicating that AICAR exerted cytoprotective properties against proteasome inhibition in ARPE-19 cells, by favoring autophagy which reduced proteasome blockade-induced toxicity.
SQSTM1/p62 protein, but not ELAVL1/ HuR protein, is degraded by autophagy Bafilomycin is known to be an autophagy inhibitor preventing the fusion of autophagosomes and lysosomes, although the effect may change between cell types and exposure time . To test how bafilomycin affects SQSTM1/p62 protein expression in ARPE-19, these cells were treated with either 50 nM bafilomycin or 5 lM MG-132 or with both agents simultaneously, and total protein extracts were analyzed by western blotting. In accordance with our previous experiments, ARPE-19 cells treated with bafilomycin displayed a dramatic increase of SQSTM1/p62 protein levels (Fig. 15A) . In addition, when cells were exposed to both bafilomycin and MG-132, there was a statistically significant increase of the SQSTM1/p62 protein amount compared to untreated (Fig. 15A ), although to a lesser extent than with bafilomycin alone, implying that SQSTM1/p62 clearance was mediated via autophagy in ARPE-19 cells. Conversely, we did not observe any change in ELAVL1/HuR protein levels after bafilomycin (Fig. 15B) , further indicating that ELAVL1/HuR protein was being degraded via proteasome.
SQSTM1/p62 protein levels in the foveomacula areas of AMD patients Since, it is uncertain that the compounds used to regulate autophagy in the cell culture model also mimic cellular aging and age-related disease we wanted to analyze these key proteins in human tissue samples. The SQSTM1/p62 staining in the foveomacular areas of the AMD patients was more extensive compared to the perimacular and peripheral areas (p < 0.001), the latter representing the internal control ( Fig. 16 and Table 1 ). The drusen were mostly SQSTM1/p62 negative while the nuclei of RPE cells were SQSTM1/p62 negative. A uniform staining of ubiquitin in RPE cells and Bruch's membrane was observed in all these regions (Fig. 17 ). There were no differences in the extent of ubiquitin staining between these regions in all groups (p > 0.1; Table 1 ). Most of the nuclei of RPE cells were ubiquitin negative and most of the drusen were strongly ubiquitin positive. The foveomacular nuclei showed less extensive immunopositivity for ELAVL1/HuR protein than the perimacular and peripheral regions (Fig. 18 ). However this difference was not statistically significant in any of the groups studied (p > 0.1; Table 1 ). The cytoplasms of RPE cells were ELAVL1/ HuR negative while the drusen were mostly ELAVL1/HuR negative. We also performed the same immunohistochemistry experiments in age-matched control samples. We found that they were mostly SQSTM1/p62 negative, especially in the macular region (Fig. 19A) ; all the nuclei of RPE cells were negative, and there were only a few SQSTM1/p62 immunopositive cytoplasms randomly distributed through-out the RPE cell layer. In the control patient samples Bruch's membrane was mostly immunonegative for ubiquitin; occasionally through-out the RPE cell layer, few cytoplasms were weakly ubiquitin positive, while all of the nuclei were negative in all the regions studied (Fig. 19B) . In these control sections, half of the nuclei showed weak immunopositivity for ELAVL1/HuR while the cytoplasms of RPE cells were negative through-out the RPE cell layer (Fig. 19C ).
Discussion
In this study, we show for the first time that in ARPE-19 cells proteasome inhibition leads to increased ELAVL1/HuR expression by acting in a dual manner: on one side inducing ELAVL1/HuR transcription and, on the other side, decreasing its protein degradation; during proteasomal inhibition ELAVL1/HuR protein binds to SQSTM1/p62 mRNA to potentiate post-transcriptionally SQSTM1/p62 expression levels in ARPE-19 cells. SQSTM1/p62 protein is cleansed by autophagy after its stationary binding to perinuclear protein aggregates during proteasome inhibition. The cleansing can be accelerated by exposure to the AMPK activator AICAR, which counteracts the MG-132 -mediated damaging effects and improves survival in RPE. Interestingly, SQSTM1/p62 rather than ELAVL1/HuR protein accumulates strongly in the drusen rich macular area in human cadaver dry AMD samples -an evidence for impaired autophagy in the pathology of AMD. These major findings are schematically summarized in Fig. 20 .
Many previous studies have focused on to the transcriptional-dependent events that affect SQSTM1/p62 expression, whereas little data is available on SQSTM1/p62 post-transcriptional control. Our findings indicate that, in response to MG-132 stimulus, the elevation in SQSTM1/p62 mRNA levels is due to the activation of specific intracellular molecular cascades that are not simply at the transcriptional level, but also involve the downstream fate of SQSTM1/p62 transcript through the RNA-binding ELAVL1/HuR protein. Indeed, we first identified within SQSTM1/p62 3 0 -UTR primary sequence the presence of ARE, that are putative ELAV-binding sites. The in vitro experiment seems to confirm our prediction, demonstrating that the recombinant HuR protein binds specifically to the ARE-bearing RNA probe of SQSTM1/p62. The ELAVL1/HuR protein capability to bind to SQSTM1/p62 mRNA was further validated in vitro by immunoprecipitation and real time qPCR experiments. In particular, the isolation of the transcripts co-immunoprecipitated with endogenous ELAVL1/ HuR protein showed that this RNA binding protein had associated with SQSTM1/p62 mRNA more prominently after proteasome inhibition in ARPE-19 cells. Proteasome inhibition caused ELAVL1/HuR protein accumulation, an increase in the amount of SQSTM1/ p62 protein and mRNA and an increase of the formation of the ELAVL1/HuR protein-SQSTM1/p62 mRNA complex. Therefore the binding of ELAVL1/HuR to a low affinity mRNA sequence, such as SQSTM1/p62, can best be explained by an alteration in the stoichiometric parameters regulating the mass action law. The increase of ELAVL1/HuR at both mRNA and protein levels in MG- MA = mean value; SD = standard deviation. Peripheral regions were selected close to the ora serrata so that it would have as few as possible drusen. The perimacular region was selected between these two so that it would contain few drusen. The extent of cytoplasmic immunopositivity was measured and its percentage in relation to the whole measurement was calculated. p-Value for SQSTM1/p62 between macularperimacular and macular-peripheral retina groups is p < 0.001. The differences among the three groups for ubiquitin and ELAVL1/HuR are not statistically significant (p > 0.1). The statistical analysis for the results was conducted with a Mann-Whitney test.
132-treated cells suggests that the ELAVL1/HuR protein up-regulation may be due not only to proteasome inhibition but also to an effect on new ELAVL1/HuR protein synthesis. In confirmation of the specific involvement of ELAVL1/HuR protein in SQSTM1/p62 post-transcriptional expression regulation, we observed that the MG-132-induced increase of SQSTM1/ p62 protein was blunted in ELAVL1/ HuR silenced RPE cells. Accordingly, we found that, in ELAVL1/HuRsilenced cells, the MG-132 exposure leads to an up-regulation of SQSTM1/p62 mRNA expression in a less extent than in MG-132-treated control cells, suggesting that physiologically the MG-132-mediated SQSTM1/p62 increase occurs at both transcriptional and post-transcriptional level, the latter one via ELAVL1/HuR protein. These findings are particularly striking since post-transcriptional mechanisms are emerging as fundamental, precise regulators of gene expression in many stress-related conditions (Abdelmohsen et al. 2008; Amadio et al. 2008) . Moreover, our results are in line with a report showing that, in human fibroblasts, MG-132 induces ELAVL1/ HuR export to the cytoplasm, where it promotes the stabilization/translation of target mRNAs (Bonelli et al. 2004) .
For the first time we show that, when co-treated with proteasome inhibitor MG-132, AICAR triggered autophagy in ARPE-19 cells, as indicated by the increase of both LC3 lipidation and autophagosome vesicles formation. As well as for AICAR, we found that also starvation alone cannot induce autophagy in ARPE-19 cells: indeed, both AICAR and starvation require the presence of MG-132 to trigger autophagic process. Notably, LC3II increase was detectable, respectively, after 0.5 hr treatment with AICAR + MG-132, and 3 hr treatment with starvation + MG-132, suggesting a different time course for autophagy activation by the two co-stimuli.
In ARPE-19 cells the MG-132-mediated increase of SQSTM1/p62 protein levels was robustly counteracted by the autophagy inducer AICAR. In contrast to SQSTM1/p62, the MG-132-triggered accumulation of ELAVL1/ HuR protein was not affected by AICAR treatment, pointing to different proteolytic mechanisms between SQSTM1/ p62 and ELAVL1/HuR: one being decreased in autophagy and the other involving the proteasomal pathway, respectively. Accordingly, a previous observation in another human cellular model reported that HuR could undergo proteasome mediated proteolysis (Abdelmohsen et al. 2009 ).
Moreover, by using pDendra2-hLC3 (MAP1LC3A/LC3) and pDendra2-hp62 (SQSTM1/p62) plasmids, with which the position of the protein in the cell can be detected from a desired time point, we analyzed protein trafficking in cells (Klionsky et al. 2012) , showing that both molecules involved in autophagy simultaneously disappeared via induction of autophagy in response to MG-132 and AICAR cotreatment. As far as we are aware, this is the first time that the binding of SQSTM1/p62 protein to perinuclear aggregates has been revealed as an irreversible process. We recently documented that when SQSTM1/p62 mRNA was silenced, ubiquitin localization in perinuclear aggregates and autophagosome formation were disturbed in ARPE-19 cells; here we show that AICAR treatment alone does not decrease SQSTM1/p62 protein levels, indicating that selective SQSTM1/p62 degradation in autophagy is favoured when ubiquitinated aggregates are present, as previously documented (Korolchuk et al. 2009a; Viiri et al. 2010) . It is noteworthy, that AICAR significantly decreased protein aggregates and improved survival in MG-132-treated RPE cells, providing clear evidence for an AICAR-mediated protective effect in this stressful condition. AICAR is a well-known autophagy inducer which acts via AMPK signalling, although it may well have other effects in different experimental models (Samari & Seglen 1998; Meley Fig. 17 . Sections of eyes with clinically diagnosed AMD immunostained for ubiquitin. The extent of Bruch's membrane immunopositivity of the retinal pigment epithelial cells (RPE, shown by arrows) and in the drusen (asterisks) was evaluated microscopically (no staining or positive staining) by selecting 5 mm long areas of foveomacular (A), perimacular (B) and peripheral (C) regions. The uniform staining of ubiquitin in RPE cells Bruch's membrane was observed in all these regions (arrows). There were no differences in the extent of staining between these regions in each group. The nuclei of RPE cells were mostly ubiquitin negative. Most of the drusen were strongly ubiquitin-positive (asterisks). (Original magnifications of 9200 and in insets 9400; Bruch's membrane shown by arrowheads). Interestingly, it has been demonstrated that in human AMD donor samples both accumulations of autophagic markers and decreased lysosomal activity can be observed (Wang et al. 2009c ). Furthermore, an effective autophagic clearance system has been recently documented in human RPE cells (Kurz et al. 2009; Ryh€ anen et al. 2009; Wang et al. 2009a; Viiri et al. 2010) . During aging, lipofuscin accumulates in lysosomes -this is evidence for a declining cellular capability to degrade proteins (Krohne et al. 2010a ). In addition, lipofuscin promotes the misfolding of intracellular proteins, which exerts an additional oxidative stress in the RPE cells (Shamsi & Boulton 2001; Kaarniranta et al. 2010) .
As recently suggested by our group (Viiri et al. 2010 ) and here confirmed in detail, the SQSTM1/p62 clearance via autophagy can be prevented by the lysosome inhibitor bafilomycin. Under bafilomycin treatment, an intense autophagosome formation, in parallel with SQSTM1/p62 accumulation, can be observed, further confirming SQSTM1/p62 as a good marker for impaired autophagy.
Our human AMD samples here studied show a significant elevation of SQSTM1/p62 protein levels in the macula, strongly indicating that SQSTM1/ p62 accumulation may be an index of impaired autophagy. In addition, most of the drusen of AMD patients were strongly ubiquitin positive, but staining for SQSTM1/p62 was observed only intracellularly. This might imply that SQSTM1/p62 is mostly degraded by the autophagic pathway and, unlike ubiquitin, SQSTM1/p62 is not exocytosed to the extracellular space of the RPE cells (Liang et al. 2007; Kaarniranta et al. 2009b; Krohne et al. 2010b) . Recently published papers have reported that ubiquitin and SQSTM1/p62 are strongly co-localized in the perinuclear aggregates (Korolchuk et al. 2009b; Viiri et al. 2010 ), but here we could detect only ubiquitin in the extracellular drusen of AMD samples. ELAVL1/HuR protein level staining in human dry AMD macula was rather reduced, although not significantly. Since ELAVL1/HuR is degraded in proteasomes, our findings provide evidence that proteasomes are active in these AMD cases, even though proteasomal activity may decrease during aging in the RPE cells (Mullins et al. 2000; Shamsi & Boulton 2001; Li et al. 2008) . As a confirmation of our hypothesis, the foveomacular areas from control no-AMD patients showed weak staining for SQSTM1/p62, ELAVL1/ HuR, ubiquitin proteins, comparable to those observed in perimacular and peripheral retina of AMD patients.
Besides many recent advances in the understanding of autophagy mechanisms, it is now widely accepted that dysfunctions in these processes have a key role in many neurodegenerative diseases, including AMD. Moreover, autophagy is increasingly emerging as a novel target of therapies aimed to counteract protein aggregation and improve cell viability; within this context, preservation of autophagy may protect RPE cell from degeneration and thus represents a potential tool to slow or even prevent the development of AMD . Fig. 19 . Sections of foveomacular areas of age-matched control eyes for SQSTM1/p62, ubiquitin and ELAVL1/HuR. The extent of cytoplasmic immunopositivity for SQSTM1/p62, Bruch's membrane immunopositivity for ubiquitin and the immunopositivity of nuclei of RPE cells for ELAVL1/HuR (foveomacular areas shown; A, B and C respectively) in the RPE cells (shown by arrows) was evaluated microscopically (no staining or positive staining). For SQSTM1/p62 there were only a few immunopositive cytoplasm's randomly distributed through-out the RPE cell layer and the nuclei were negative. Bruch's membrane (shown by arrowheads) was immunopositive for ubiquitin occasionally through-out the RPE cell layer in very small amounts while all of the nuclei were negative. Half of the nuclei showed minor immunopositivity for ELAVL1/HuR while the cytoplasm's of RPE cells were negative. The foveomacular areas showed no difference in immunohistochemical stainings when compared to areas of perimacular and peripheral retina in all of the proteins studied. (Original magnifications of 9200 and in insets 9400). Fig. 20 . Summary of the results. The proteasome inhibitor MG-132 down-regulates (À) the ubiquitin-proteasome pathway (UPP). AMPK-activator AICAR and proteasome inhibitor MG-132 co-treatment activates (+) the autophagy. UPP inhibition significantly increases (+) SQSTM1/p62 protein levels, while autophagy induction during UPP inhibition robustly decreases (À) SQSTM1/p62 protein levels. Since SQSTM1/p62 localizes to aggregates, the decreasing of SQSTM1/p62 reveals its autophagy clearance. In addition, proteasome inhibition significantly increases ELAVL1/HuR protein levels by itself and during the autophagy induction (+). Proteasome inhibition induces a positive regulation of SQSTM1/p62 expression that occurs also at post-transcriptional level via ELAVL1/HuR protein (+). Activated autophagy is able to completely abolish the MG-132-induced protein aggregation (À), which, in turn improves the cell vitality. Ubiquitin is also found in intracellular aggregates in ARPE-19 cells as well as from drusens. In contrast, SQSTM1/ p62 is found only in the intracellular aggregates in ARPE-19 cells, but not in drusens. However, SQSTM1/p62 levels were high in macular area of RPE cells revealing impaired autophagy. What is the relation between drusen and intracellular aggregates remains still unknown. Red lines with minus symbol represent inhibiting and decreasing events in ARPE-19 cells. Black lines and plus symbol represent activating and increasing events in the ARPE-19 cell. Zero (0) and dark blue line indicate neutral effects in the ARPE-19 cell. UPP: ubiquitin-proteasome pathway.
Hsp70 Binds Reversibly to Proteasome Inhibitor-induced Protein Aggregates and Evades Autophagic Clearance in ARPE-19 Cells Abstract
Age-related macular degeneration (AMD) is characterized primarily by degeneration of the macular retinal pigment epithelium (RPE) that secondarily leads to cell death of photoreceptors and impaired central vision. Hallmarks of AMD are accumulation of lysosomal lipofuscin and extracellular drusen, which indicate impaired proteolysis in RPE cells. Cellular proteostasis is strongly regulated by molecular chaperones such as Hsp70 and proteasomal and autophagic clearance systems. We have recently shown that autophagy receptor SQSTM1/p62 binds irreversibly to proteasome inhibitor-induced perinuclear protein aggregates and undergoes autophagic clearance in RPE cell cultures. Revealing decreased autophagy, SQSTM1/p62 accumulates in macular area of donor AMD patient samples. In this study, we show that Hsp70 binds reversibly to proteasome inhibitor-induced perinuclear protein aggregates and does not become degraded by autophagy in ARPE-19 cells. Our observation reveals new opportunities to use a cytoprotective Hsp70 as a therapy target in the prevention of RPE cell degeneration and development of AMD.
Introduction
Age-related macular degeneration (AMD), the leading cause of irreversible blindness in the Western world, is characterized primarily by degeneration of the macular retinal pigment epithelium (RPE; Kaarniranta et al. 2011) . RPE damage leads secondarily to cell death of photoreceptors (rods and cones) and impaired vision. The cells of RPE are exposed to chronic oxidative stress originated mainly from three sources: (i) high levels of oxygen consumption, (ii) exposure to lipid peroxidation products derived from the ingestion of photoreceptor outer segments, and (iii) exposure to constant light stimuli. Chronic oxidative stress may evoke misfolding and aggregation of proteins especially during aging. Heat shock proteins (Hsps) attempt to repair the misfolding damage. If this fails, soluble proteins become ubiquitinated and targeted into proteasomes for degradation (Jung et al. 2009; Kaarniranta et al. 2013) . Increased levels of Hsps have been observed in RPE cells with accumulated lipofuscin and in retina samples of AMD patients (Schutt et al. 2002; Decanini et al. 2007 ). Moreover, proteasomal activity declines during aging, which leads to aggregation of oxidized and ubiquitinated proteins, as has been documented to happen in RPE (Li et al. 2008; Viiri et al. 2013) . Impaired proteasomal clearance in RPE cells induces selective macroautophagy (referred to as autophagy; Viiri et al. 2010 Viiri et al. , 2013 , which is the most prevalent form of autophagy. It involves formation of a double-membrane structure (autophagosome) and engulfment of cytoplasmic proteins, lipids and damaged organelles (Klionsky et al. 2012 ). Thereafter, autophagosomes fuse with primary lysosomes, and their contents become degraded by lysosomal enzymes ).
Cellular homeostasis is largely dependent on the quality control of proteins, which is called proteostasis (Tokarz et al. 2013) . Hsp70 is one of the key chaperone proteins in the regulation of proteostasis together with proteasomal and autophagic clearance (Tokarz et al. 2013 ). SQSTM1/p62 (Sequestosome 1) is the best-characterized and most ubiquitously expressed autophagy adaptor that connects proteasomal clearance with autophagy (Bjørkøy et al. 2005; Komatsu et al. 2007; Kaarniranta et al. 2009b; Pankiv et al. 2010; Viiri et al. 2010 Viiri et al. , 2013 . We have previously shown that SQSTM1/ p62 binds irreversibly to perinuclear protein aggregates and undergoes autophagic clearance (Viiri et al. 2013 ). On the other hand, alleviation of autophagy is usually accompanied by accumulation of SQSTM1/p62, especially on areas that are rich of ubiquitin-stained protein aggregates, as recently reported in AMD patients (Viiri et al. 2010 (Viiri et al. , 2013 .
When proteasomal clearance becomes inhibited in RPE cells, Hsp70 accumulates in same protein aggregates with SQSTM1/p62 Viiri et al. 2013 ). SQSTM1/p62 rather than Hsp70 is considered to be a marker for autophagic activity (Viiri et al. 2010 (Viiri et al. , 2013 . In this study, we show that Hsp70 binds in a reversible manner to proteasome inhibitor-induced perinuclear protein aggregates and does not become degraded by autophagy in ARPE-19 cells.
Materials and methods
ARPE-19 cells originated from human retinal pigment epithelium were obtained from the American Type Culture Collection (ATCC). The cells were grown to confluence in a humidified 10% CO 2 atmosphere at 37°C in Dulbecco's MEM/Nut MIX F-12 (1:1) medium (Life Technologies, 21331) containing 10% inactivated fetal bovine serum (Hyclone, SV30160-03), 100 units/ml penicillin, 100 lg/ml streptomycin (Lonza, DE17-602E), and 2 mM L-glutamine (Lonza, BE17-605E). In order to induce protein aggregates, the cells were exposed to 5 lM of MG-132 proteasome inhibitor (Calbiochem, 474790). Lysosomal function was disturbed by 50 nM of bafilomycin A1 (Sigma, B1793). Autophagy was activated with the AMPK (AMP-activated protein kinase) activator AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside; Toronto Research Chemical, A611700) at 2 mM concentration or induced by starving the cells in serumfree medium. All exposures lasted for 24 hr.
Transmission electron microscopy
Cell culture samples were prefixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) for 2 hr at room temperature. After 15 min washing with 0.1 M phosphate buffer, the cells were post-fixed in 1% osmium tetroxide and 0.1 M phosphate buffer for 1 hr, and washed with phosphate buffer for 15 min prior to standard ethanol dehydration. Subsequently, the samples were infiltrated and embedded in LX-112 resin. Polymerization was carried out at 37°C for 24 hr and at 60°C for 48 hr. The sections were examined with a JEM-2100F transmission electron microscope (Jeol) at 200 kV.
Western blotting
For Western blotting, whole cell extracts containing 20 lg of protein were run in 10% SDS-PAGE gels and then transferred to nitrocellulose membranes (Amersham Biosciences, Little Chalfont, The United Kingdom) using a semi-dry transfer apparatus (Bio-Rad Laboratories, Hercules, California, The United States of America). Successful transfer of proteins from gels to membranes was monitored by Ponceau S staining (Sigma). The membranes were blocked in 0.3% Tween 20/PBS (phosphate-buffered saline) containing 3% fat-free dry milk for 1.5 hr at room temperature (RT). Subsequently, the membranes were incubated overnight at 4°C with a mouse monoclonal Hsp70 antibody (StressGen, San Diego, California, The United States of America) or with a mouse monoclonal anti-a-tubulin (Sigma). Primary antibodies were diluted 1:5000 and 1:8000, respectively, in 0.3% Tween 20/PBS containing 0.5% bovine serum albumin. After three 10-min washes with 0.3% Tween 20/PBS, the membranes were incubated for 2 hr at RT with horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences). Secondary antibodies were diluted 1:20 000 for Hsp70 and 1:10 000 for a-tubulin in 0.3% Tween 20/PBS containing 3% fat-free dry milk. Before detection, all membranes were washed as mentioned above. Protein-antibody complexes were detected with an enhanced chemiluminescence method (Millipore, Darmstadt, Germany).
pDendra2-Hsp70 fusion plasmid construction
The functional open reading frame (ORF) of human Hsp70 A1A gene (NCBI Nucleotide accession no. NM_005345) was amplified from DNase-treated (DNase I, Roche) total RNA, which was extracted using the Eurozol reagent (Euroclone) from human ARPE-19 cells. RNA was reverse-transcribed by MultiScribe reverse transcriptase (Applied Biosystems), and Hsp70 cDNA was amplified with Phusion Hot start DNA polymerase (Finnzymes). Primers were 5 0 -ATA CTC GAG atA TGG CCA AAG CCG C (forward) and 5 0 -AAT AAG CTT gCT AAT CTA CCT CCT CAA TGG TG (reverse), containing target sites for restriction endonucleases XhoI and HindIII (italics) and stuffers (minuscules) for in-frame ligation. Sites for the initiation and termination of translation are in boldface.
Sticky ends for the amplified Hsp70 ORF as well as for the multiple cloning site of the vector pDendra2-C (Evrogen; Gurskaya et al. 2006) were produced with the above-mentioned restriction endonucleases (MBI Fermentas). Ligated (T4 DNA Ligase, Roche) DNA containing a fusion gene of Dendra2 and Hsp70 was transfected into competent DH5a E. coli cells, which were prepared using the protocol described by Inoue et al. (1990) . Following the bacterial growth, plasmids were purified as previously described (Sambrook et al. 1990 ). Integrity of the construct, named pDendra2-hHsp70, was determined initially by the restriction endonuclease digestion analysis and finally by sequencing the junction sites and the entire inserted Hsp70 ORF.
The plasmid pDendra2-hp62 producing a fusion protein containing Dendra2 and human SQSTM1/p62, analogous to pDendra2-hHsp70 described above, was prepared as previously described (Viiri et al. 2013 ). Preliminarily, the structure and functionality of the fusion proteins were initially monitored using RT-PCR amplification of a 365-bp fragment flanking one junction and by Western hybridization with a Hsp70 antibody (StressGen) detecting the fusion protein (not shown).
Plasmid transfection and confocal microscopy
The pDendra2 fusion plasmids were transfected into subconfluent cultures of ARPE-19 cells using the ExGen 500 in vitro transfection reagent (MBI Fermentas) following manufacturer's instructions. In all transfection experiments for confocal microscopy, ExGen 500 in vitro Transfection Reagent (MBI Fermentas) was used according to the manufacturer's protocol. ARPE-19 cells were cultured in 8-well plates (lSlide, ibiTreat, tissue culture treated, Ibidi) to subconfluent density. Thereafter, the pDendra2 fusion plasmids containing 1 lg DNA per well were added, and the cells were incubated for 24 hr. Subsequently, the culture medium was changed and MG-132 (5 lM) and bafilomycin (50 nM) were added for 24 hr. Transfected cells were exposed to UV radiation (405 nm), which changed the photo-switchable colour of Dendra2 from green to red. Fluorescent images were obtained with a Zeiss Axio Observer inverted microscope (409 NA 1.3 or 639 NA 1.4 oil objectives) equipped with the Zeiss LSM 700 confocal module (Carl Zeiss). For live cell imaging, Zeiss XL-LSM S1 incubator with temperature and CO2 controls was utilized. ZEN 2009 software (Carl Zeiss) was used for image processing.
Results
We recently documented that SQSTM1/p62, a shuttle protein between proteasomal and autophagic clearance, binds permanently in perinuclear aggregates and subsequently undergoes autophagic clearance (Viiri et al. 2013) . Since Hsp70 binds to the same aggregates (16), we wanted to evaluate whether the binding of Hsp70 is a reversible or an irreversible process. First, ARPE-19 cells were exposed to 5 lM concentration of MG-132 for 24 hr, which evoked strong formation of perinuclear protein aggregates (Fig. 21; Ryh€ anen et al. 2009 ). Then pDendra2-hHsp70 fusion plasmid construct was transfected to the cells and confocal microscopy was used for live cell imaging. The movement of pDendra2-hHsp70 fusion protein was evaluated after photo conversion (Fig. 22) . We detected that Hsp70 protein moved from the converted area to other parts of the cell, which suggests that the binding of Hsp70 to protein aggregates is reversible. As a comparison, pDendra2-hp62 did not leave the exposed area (Fig. 22, panel C ; Viiri et al. 2013) .
Bafilomycin is known to inhibit autophagy by preventing the fusion of autophagosomes with lysosomes (Klionsky et al. 2012) . To examine how bafilomycin affects the expression of Hsp70 protein in ARPE-19, the cells were treated either with 50 nM of bafilomycin, 5 lM of MG-132 or both. Thereafter, total protein extracts were analysed for the expression of Hsp70 using the western blotting technique. In contrast to our previous observations with SQSTM1/p62 (Viiri et al. 2013 ), ARPE-19 cells treated with bafilomycin displayed no changes in Hsp70 protein levels (Fig. 23) . When the cells were exposed simultaneously to both bafilomycin and MG-132, there was a significant increase in the amount of Hsp70 protein. A similar increase in the levels of Hsp70 was seen in cells treated with MG-132 alone. This suggested that Hsp70 is not degraded by autophagy.
In order to confirm this hypothesis, possible effects of AICAR and serum starvation on the Hsp70 expression under MG-132 stimulation were studied. Induction of autophagy by either way did not change the Hsp70 protein levels (Fig. 24) . These results support the idea that Hsp70, in contrast to SQSTM1/p62, does not bind permanently to proteasome inhibitor-induced protein aggregates and does not undergo the autophagic clearance.
Discussion
In the present study, we have shown that the best-known molecular chaperone Hsp70 binds to perinuclear protein aggregates by a reversible mechanism under proteasome inhibition in human retinal ARPE-19 cells. We have recently shown using pDendra2-hLC3 (MAP1LC3A/LC3) and pDendra2-hp62 (SQSTM1/p62) plasmids, with which localisation of the proteins in a cell can be detected at a desired time point, that both LC3 and SQSTM1/ p62 disappeared via autophagic clearance in response to the inhibition of proteasomes and the induction of autophagy. The binding of SQSTM1/ p62 protein to perinuclear aggregates was observed to be an irreversible process (Klionsky et al. 2012; Viiri et al. 2013) . In contrast to our previous results, we show here by pDendra2-hHsp70 fusion plasmid construction analyses that Hsp70 moves from protein aggregates during proteasome inhibition, indicating reversible binding of Hsp70 to protein aggregates.
Blocking the expression of SQSTM1/ p62 rather than Hsp70 using mRNA silencing results in decreased autophagosome formation in ARPE-19 cells (Viiri et al. 2013 ). However, both of them had similar cytoprotective capacity under proteasome inhibition. Cytoprotection was obviously involved in the repairing chaperone function of Hsp70, while SQSTM1/p62 regulated the induction of autophagic clearance. Once autophagy was induced during proteasome inhibition, SQSTM1/p62 degradation also became accelerated. In this study, we have shown that the induction of autophagy by AICAR or by starvation, or the inhibition of autophagy by bafilomycin, did not change Hsp70 levels under proteasome inhibition. This indicates that Hsp70 is protected from autophagic clearance. Hsp70 consists of two major functional domains; the amino-terminal domain that possesses the ATP/ADP binding site as well as the ATPase activity, and the carboxy-terminal domain, which contains the binding site for substrate peptides (da Silva & Borges 2011). In the ATP-bound state, substrates can easily bind to and dissociate from Hsp70. When ATP is hydrolysed to ADP, the affinity of a substrate to Hsp70 becomes increased (Bukau & Horwich 1998 ). An important feature in the Hsp70's cycle is that chaperone proteins have several cochaperones that modulate substrate interactions. We found that Hsp70 binds in a reversible manner to proteasome inhibitor-induced protein aggregates. This process might be controlled by the ATP/ADP regulation cycle. Post-translational modifications of Hsp70 such as SUMOylation, ubiquitination or glycosylation may also control the binding activity of Hsp70 to the client proteins in aggresomes and prevent its autophagic clearance (Guinez et al. 2008; Mishra et al. 2009; Janer et al. 2010; Lee et al. 2012; Wang et al. 2013; Yang et al. 2013) . There is evidence that in contrast to SQSTM1/p62, Hsp70 favours proteasomal clearance in certain stress conditions (Lee et al. 2012) .
Damage in cellular macromolecules accumulates during aging and tissue degeneration in postmitotic cells, such as RPE cells . It has recently been proposed that declining heat shock response, reduced levels of Hsps, and the resultant loss of protein quality control may exacerbate protein damage during aging (Calderwood et al. 2009; Rodgers et al. 2009; Kinnunen et al. 2012; Klettner et al. 2013 ). Molecular Hsp70 chaperone therapy might be a new formulation strategy in the treatment of retinal pigment epithelium and AMD (Klettner 2004) . RPE cells are phagocytic and they can internalise extracellular material as occurs e.g. with photoreceptor outer segments during normal visual cycle. The shed photoreceptor outer segment particles are taken up by RPE via endocytic and phagocytic processes and degraded in lysosomes . In aged RPE cells, however, lysosomal enzyme activity is decreased, which leads to harmful lipofuscin accumulation and reflects the severity of AMD (Krohne et al. 2010a ). In the Hsp70-based therapy, proteins should be targeted to lysosomes due to phagocytic process (Yu et al. 2001) . Interestingly, Hsp70 has been found in lysosomal fractions of RPE cells (Schutt et al. 2002; Ryh€ anen et al. 2009 ). It might be hypothesized that Hsp70 as a molecular chaperone keeps lysosomal enzymes functionally active, prevents lipofuscin accumulation in RPE cells and thereby suppresses the development of AMD (Karlsson et al. 2013) . Hsp70 has also anti-inflammatory capacity (Paimela et al. 2011) . Inflammation is a central hallmark in the pathogenesis of AMD. Therefore, Hsp70 might also prevent inflammatory signalling in RPE cells. The present data importantly show that Hsp70 is protected from lysosomal clearance system and thus provide opportunity to develop its use in protein, drug or laser therapy for the prevention of AMD.
Introduction
Age-related macular degeneration (AMD) is the most common reason for legal blindness in the developed countries. Phenotypically, AMD can be divided into two main groups: dry (atrophic) and wet (exudative) type and further subdivided into early and late stage disease ). The early stage of dry AMD is asymptomatic, although pigment mottling, accumulation of intracellular lysosomal lipofuscin, and extracellular drusen deposits can be detected in ophthalmological examinations. The late stage of dry AMD, also known as geographic atrophy, is characterized by discrete areas of RPE loss and impairment of the overlying retinal photoreceptor cells and severe visual loss (Kinnunen et al. 2012; Klettner et al. 2013 ). Today there is no effective treatment for dry AMD, although omega-fatty acid and antioxidants are usually recommended for high risk AMD patients Chew et al. 2013) . In wet AMD, aberrant blood vessels sprout from the choroidal capillaries and penetrate through the Bruch's membrane leading to subretinal membranes, hemorrhage, retinal edema and damage to retinal cells. This proliferative process is called choroidal neovascularisation (CNV). Wet AMD results in a rapid loss of vision if not treated. A major factor in the development of neovascularization is Vascular Endothelial Growth Factor (VEGF) A, which is therapeutically inhibited to treat wet AMD (Klettner 2014) . In addition to its pathological effects, VEGF-A has important physiological functions both systemically and in the retina. Current VEGF-antagonists are the Fab-Fragment ranibizumab (Lucentis), the fusion protein aflibercept (Eylea) and the off-label used antibody bevacizumab (Avastin). In addition, the aptamer pegaptanib (Macugen) is approved for the treatment of AMD, but rarely used. These molecules differ in molecular size and structure which impacts on their pharmacological behavior such as their effects on retinal cells, ocular and systemic clearance, or systemic VEGF-A inhibition. Although all these drugs have been shown to be equally effective in the treatment of wet AMD, the respective therapeutic molecule may have different systemic and/or retinal effects especially after prolonged usage (The CATT Research Group 2011; IVAN Study Investigators et al. 2012; Schmidt-Erfurth et al. 2014) .
Bevacizumab is a recombinant fulllength humanized antibody with a molecular weight of 149-kDa, binding to all VEGF-A isoforms and reducing angiogenesis and vascular permeability. It was originally developed to target pathologic angiogenesis in malignant tumors and approved by the authorities for the treatment of metastatic colorectal cancer (Klettner 2014) . However, mostly because of economic reasons, bevacizumab is widely used intravitreally as an off-label treatment for proliferative eye diseases, such as CNV related to AMD, diabetic macular edema and macular edema caused by retinal vein occlusion. The intravitreal injection of 1.25 mg of bevacizumab has been shown to be comparable in efficacy to the officially approved treatment with ranibizumab. The CATT Study (The Comparison of Age-Related Macular Degeneration Treatment Trials) and IVAN Study (Inhibit VEGF in Age Related Choroidal Neovascularization) compared the relative safety and effectiveness of bevacizumab and ranibizumab in treatment (The CATT Research Group 2011; IVAN Study Investigators et al. 2012) . Patients with newly diagnosed exudative AMD were followed up for 2 years, and the results showed similar outcomes using either drug, with bevacizumab showing non-inferiority to ranibizumab.
The half-life in vitreous humour is similar with both compounds -7 days for bevacizumab and 9 days for ranibizumab, resulting in similar treatment intervals (Drolet et al. 2000; Zhu et al. 2008) . However, the systemic half-life is different, i.e. 20 days for bevacizumab versus 6 hr for ranibizumab, and the maximum systemic exposure with 1.25 mg bevacizumab is 20-690 ng/ml and with 0.5 mg ranibizumab 0.8-2.9 ng/ml (Xu et al. 2013) . Since the systemic exposure is lower with ranibizumab, it may be associated with lower systemic toxicity (Schmidt-Erfurth & Pruente 2007). In fact, it has been shown that intravitreal injections of bevacizumab decrease VEGF levels in blood by up to 117-fold within 1 day and by 4-fold up to 1 month later. This decrease is similar to that achieved with intravenous therapy, and it is possible that intravitreal bevacizumab may suppress baseline physiologic VEGF activity (Matsuyama et al. 2010; Qian et al. 2011) . Furthermore, bevacizumab has been detected and associated with regression of contralateral proliferative diabetic retinopathy and iris neovascularization in rabbits after intravitreal injection in contralateral eyes .
In preclinical safety studies with bevacizumab, the compound was shown to be safe in general. In several studies bevacizumab showed no direct cytotoxicity in various cultured ocular cell lines or in cultured retinas (Luthra et al. 2006; L€ uke et al. 2007) . Similarly, in short-term in vivo rabbit models, intravitreal bevacizumab did not cause any serious ocular toxicity (Bakri et al. 2006; Shahar et al. 2006) . However, in one study mitochondrial disruption was observed in the photoreceptor inner segments, and proteins associated with apoptosis were detected in the outer plexiform, outer nuclear, and photoreceptor layers (Inan et al. 2007 ). In addition, bevacizumab, but not ranibizumab, has been shown to accumulate in the RPE cells, which may reduce heterophagic ability in these cells Klettner et al. 2010) .
Age-related macular degeneration (AMD) is a neurodegenerative aggregation disease that shares its cellular pathology with Alzheimerś disease (Kaarniranta et al. 2011) . Recently, it has been observed that one crucial mechanism behind AMD is impaired proteasomal and lysosomal proteolysis that associates with the accumulation of lipofuscin and drusen (Kaarniranta et al. 2010 Viiri et al. 2013) . Autophagy is a basic lysosomal catabolic mechanism which 'self eats' cellular components which are unnecessary or dysfunctional for the cell Viiri et al. 2013; Kivinen et al. 2014) . Autophagy comprises three intracellular pathways in eukaryotic cells, which are macroautophagy (hereafter referred to as autophagy), microautophagy, and chaperone-mediated autophagy. Autophagy has a key role in normal cellular homeostasis, but it is also triggered as an adaptive response during AMD associated stress conditions Klettner et al. 2013) . Autophagy process begins with the formation of isolation membranes called phagophores; these later then become elongated and surround portions of cytoplasm containing oligomeric protein complexes and organelles to form mature double membrane autophagosomes. The autophagosomes fuse with lysosomes and their content is then degraded by lysosomal enzymes. Failure of autophagy in aged postmitotic cells, including RPE cells, can result in accumulation of aggregate-prone proteins, cellular degeneration and finally cell death that secondarily leads to photoreceptor damage and visual loss (Viiri et al. 2010 (Viiri et al. , 2013 . SQSTM1/p62 (Sequestosome 1) is the best-characterized and ubiquitously expressed autophagy receptor that connects proteasomal clearance with lysosomes (Bjørkøy et al. 2005; Komatsu et al. 2007; Korolchuk et al. 2009b; Pankiv et al. 2010; Viiri et al. 2010) . Alleviation of autophagy is usually accompanied by an accumulation of SQSTM1/p62 mostly in large perinuclear aggregates or inclusion bodies which are also positive for ubiquitin. In this study, we show that bevacizumab does not affect autophagy clearance in ARPE-19 cell during proteasome inhibition and protein aggregation.
Materials and methods
Cell culture ARPE-19 human RPE cells were obtained from the American Type Culture Collection (ATCC). The cells were grown to confluence in a humidified 10% CO2 atmosphere at 37°C in Dulbecco's MEM/Nut MIX F-12 (1:1) medium (Life Technologies, 21331) containing 10% inactivated fetal bovine serum (Hyclone, SV30160-03), 100 units/ml penicillin and 100 mg/ml streptomycin (Lonza, DE17-602E) and 2 mM L-glutamine (Lonza, BE17-605E). The cells were exposed solely to 0.25 mg/ml bevacizumab (Pharmacy of Kuopio University Hospital) or 1 lM MG-132 proteasome inhibitor (Calbiochem, 474790) or combination of bevacizumab and MG-132 for 0.5, 3, 12 and 24 hr. Moreover, the cells were exposed solely to 0.25 mg/ml bevacizumab for 1 hr, 4 hr, 1 day, 3 days or 7 days. To prevent autophagy flux, 50 nM bafilomycin A1 (Sigma, B1793) for 1 and 4 hr was used.
Western blotting
The whole cell extracts were prepared in M-PER (Mammalian Protein Extraction Reagent, Thermo Scientific, 78501) according to the manufacturer's protocol. Proteins were diluted in 39 sodium dodecyl sulphate (SDS) protein gel loading solution, boiled for 5 minutes, separated on 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and processed following standard procedures. The rabbit polyclonal ubiquitin antibody (DakoCytomation, Z0458) was diluted in 3% milk powder, 0.3% Tween 20/PBS at 1:500. Secondary antibody was diluted in 3% milk powder, 0.3% Tween 20/PBS at 1:20 000. The mouse monoclonal anti-SQSTM1/p62 (Santa Cruz Biotech, sc-28359) was diluted in 0.5% bovine serum albumin, 0.3% Tween 20/PBS at 1:1000. Secondary antibody was diluted in 3% milk powder, 0.3% Tween 20/PBS at 1:20 000. The mouse monoclonal anti-a-tubulin (Sigma, T5168) was diluted in 1% milk powder, 0.05% Tween 20/PBS at 1:8000. Secondary antibody was diluted in 1% milk powder, 0.05% Tween 20/PBS at 1:10 000. The rabbit monoclonal anti-MAP1LC3A/LC3 (anti-LC3, microtubule-associated protein light chain 3A; Cell Signaling, 3868) was diluted in 5% bovine serum albumin, 0.1% Tween 20/PBS at 1:1000. Secondary antibody was diluted in 3% milk powder, 0.1% Tween 20/PBS at 1:2000.
The nitrocellulose membranes signals were detected by chemiluminescence.
Experiments were performed in duplicate for each cell preparation and atubulin was used to normalize the data. Statistical analysis of western blot data was performed on the densitometric values obtained with the NIH image software 1.61 (downloadable at http:// rsb.info.nih.gov/nihimage) and Quantity OneH software.
Transmission electron microscopy ARPE-19 cell culture samples were prefixed with 3% glutaraldehyde in PBS at 4°C overnight. After 3 9 10 min washing in PBS, the samples were post-fixed in 2% osmium tetroxide for 60 min, washed with phosphate buffer for 15 min prior to standard ethanol dehydration, and . Ultrathin (60 nm) sections were cut and examined with a Zeiss 902 electron microscope. Autophagic vesicles were manually counted. Eight cells were randomly selected from each group for counting autophagic vesicles. Statistical analysis was performed using SPSS (v. 19; IBM, SPSS Inc). The significance of differences between control and treated groups was analyzed with Mann-Whitney U-test. A p-value of 0.05 or less was considered significant.
Results
First, the effect of proteasome inhibition on expression of ubiquitin protein conjugates, SQSTM1/p62 and MAP1LC3A/LC3 were studied in human ARPE-19 RPE cells. The cells were either non-stressed or exposed to bevacizumab 0.25 mg/ml or 1 lM MG-132, or simultaneously exposed to both of the drugs for 30 min, 3, 6 and 24 hr and analyzed by western blotting. A robust increase in the ubiquitin protein conjugates were observed in all the studied time points during proteasome inhibition (Fig. 25) . Increased SQSTM1/p62 levels were seen at the 6 and 24 hr time points in response to proteasome inhibition. Increased lipidation of the MAP1LC3A/LC3 was detected at the 24 hr time point during proteasome inhibition revealing autophagy activation. No changes of protein levels were found in samples treated solely with bevacizumab which indicates a good tolerability.
To study the long-term effect of bevacizumab (0.25 mg/ml) on the expression of ubiquitin protein conjugates, SQSTM1/p62 and MAP1LC3A/ LC3, the cells were either non-stressed or exposed to bevacizumab for 1, 4 hr, 1 and 7 days and analyzed by western blotting. Bevacizumab did not change the expression levels of any of the proteins studied (Fig. 26) .
The ultrastructure and amount of autophagosomes were examined using transmission electron microscopy. Neither in control or in 0.25 mg/ml bevacizumab cells treated for 1 hr or 4 hr, cellular abnormalities or changes in autophagosomes were observed ( Fig. 27A and Table 2 ). Bafilomycin is known to be an autophagy inhibitor preventing the fusion of autophagosomes and lysosomes, but robustly increasing the amount of autophagosomes (Klionsky et al. 2012; Viiri et al. 2013 ). To provide a positive control, the cells were either non-stressed or exposed to 50 nM bafilomycin for 1 hr or 4 hr. As expected, there was a clear statistically significant difference between control and bafilomycin groups studied; p > 0.01 ( Fig. 27B and Table 3 ). We did not observe cellular abnormalities or changes in autophagosomes for a long time exposure up to 7 days with bevacizumab ( Fig. 28A and Table 4) . Fig. 26 . Western blotting from the ARPE-19 cells exposed solely to 0.25 mg/ml bevacizumab or 1 lM MG-132 proteasome inhibitor or combination of bevacizumab and MG-132 for 1 hr, 4 hr, 1 day, 3 days or 7 days. a -tubulin was used as a loading control. Fig. 27 . AB Transmission electron microscope pictures from RPE cells predisposed to 0.25 mg/ml bevacizumab for 1 and 4 hr (A). RPE cells cultured in normal medium were used as a control. To provide a positive control the cells were either non-stressed or exposed to 50 nM bafilomycin for 1 hr or 4 hr (B).
However, when cells were exposed to 50 nM bafilomycin, already at 24 hr a clear statistically significant difference between control and bafilomycin groups studied could be observed; p > 0.001 ( Fig. 28B and Table 5 ).
Discussion
We show that bevacizumab does not affect autophagy clearance in ARPE-19 cells during accumulation of intracellular protein aggregates and proteasome inhibition. Moreover, in contrast to bafilomycin, bevacizumab does not affect autophagy during short or long time exposures. Our observations reveal that bevacizumab is well tolerated by RPE cells and does not disturb the crucial autophagy clearance system.
In human AMD donor samples both accumulations of autophagic markers and decreased lysosomal activity can be observed (Wang et al. 2009c ). Furthermore, an effective autophagic clearance system has recently been documented in human RPE cells (Kurz et al. 2009; Ryh€ anen et al. 2009; Wang et al. 2009b; Viiri et al. 2010 Viiri et al. , 2013 . Indicating a declined proteolysis in RPE cells during aging, lipofuscin accumulates in lysosomes and drusen between Bruch́s membrane and RPE cell layer (Krohne et al. 2010a; Kaarniranta et al. 2013) . Lipofuscin is a toxic compound in RPE cells which promotes the damage of mitochondria and misfolding of intracellular proteins, creating an additional oxidative stress in the RPE cells (Shamsi & Boulton 2001; Kaarniranta et al. 2010) . When autophagy flux is inhibited by lysosome inhibitors, such as bafilomycin, it induces autophagosome formation but does not increase lysosomal proteolysis due to the decreased MA = mean value; N = samples analyzed; SD = standard deviation. Control cells were cultured in normal medium. Autophagosomes were calculated from pictures taken with a transmission electron microscope. There was no statistically significant difference between any of the groups studied (p > 0.1). To provide a positive control the cells were either non-stressed or exposed to 50 nM bafilomycin for 24 hr (B). lysosomal enzyme activity. With both short and long term exposure, bafilomycin evoked an intense autophagosome formation, in parallel with autophagy receptor SQSTM1/p62 accumulation (Viiri et al. 2013 ). Bevacizumab did not change SQSTM1/p62 expression levels confirming that there is no detrimental effect on autophagy clearance. Ranibizumab, aflibercept and bevacizumab have been shown to be welltolerated and they have equal efficacy in the treatment outcomes for wet AMD (Klettner & Roider 2008; The CATT Research Group 2011; IVAN Study Investigators et al. 2012; Schmidt-Erfurth et al. 2014) . These molecules differ in molecular size, structure, binding activity and binding targets which may result in different effects at the cellular level (Klettner 2014) . At concentrations used in clinical practice, there are no toxic effects on retinal pigment epithelial cells, neural retina, or endothelial cells in vitro (Luthra et al. 2006 (Luthra et al. , 2013 Spitzer et al. 2007; Miguel et al. 2012; Schnichels et al. 2013) . However, bevacizumab exposure has been documented to decrease in mitochondrial activity in both the proliferating and non-proliferating endothelial cells in vitro (Luthra et al. 2013 ). This suggests a selective action of bevacizumab on endothelial cells. Moreover, bevacizumab may accumulate in RPE cells, decrease heterophagy and exert pro-fibrotic effects on human RPE cells Klettner et al. 2010; Chen et al. 2012; Kaarniranta et al. 2013) . These effects of bevacizumab can be considered as complications that may affect longterm bevacizumab treatment results. All those detrimental effects may be anticipated to affect autophagy, a key proteostasis regulator, in normal cellular homeostasis, but also an adaptive response during AMD associated stress conditions Klettner et al. 2013) . In our study, we were not able to show any effects of bevacizumab on autophagy regulation. In that aspect, bevacizumab might be considered as a safe drug in the regulation of cellular proteostasis. Comparable studies with ranibizumab and aflibercept on autophagy regulation would be interesting to carry out.
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed countries (Pascolini et al. 2002) . The prevalence of the disease is expected to increase in the future. However, the disease may even occur in middle aged subjects, especially in active individuals under the age of 55. As the lesion(s) continues, patients may experience further reductions in their quality of life indices (Rein et al. 2009 ). Primarily, AMD is characterized by degeneration of the retinal pigment epithelium (RPE) which subsequently leads to the death of rods and cones, the cells actually responsible for vision, especially in the macular region of the retina (Klettner et al. 2013) . Phenotypically AMD can be divided into two main groups: dry or atrophic and wet or exudative forms. Furthermore, the disease can be subdivided into early and late stage disease . Dry AMD can gradually progress over a period of months or even years to geographic atrophy; it is particularly treacherous because it may not display any symptoms in its early stages (Sunness et al. 1997; Age-Related Eye Disease Study Research Group 2000; Kaarniranta et al. 2010) . Dry AMD may take even years to develop whereas wet AMD may progress rapidly within a few weeks. Choroidal neovascularization, a process in which abnormal blood vessels grow from the choroidal capillaries through Bruch's membrane into the retina, leads to hemorrhage and retinal oedema, resulting in a loss of vision if not rapidly treated with anti-VEGF (Vascular Epithelial Growth Factor) therapeutics (Zhu et al. 2008; Klettner 2014; Tolentino et al. 2014 ).
The maintenance of protein homeostasis, also referred to as ''-teostasis', refers to the multiple pathways that are involved in protein synthesis and its regulation i.e. folding, translocation, and degradation. In addition to increased oxidative stress and the presence of inflammation, a failure in proteostasis may be one of the underlying mechanisms responsible for the cascade of events leading to RPE degeneration and the development of AMD (Xu & Ren 2015; Ferrington et al. 2016; Kauppinen et al. 2016) . RPE cells ingest and degrade the used tips of photoreceptor outer segments and thus clear them from the tissue (Rakoczy et al. 1994 ). The ubiquitin-proteasome pathway (UPP) and autophagy are central degradation systems in mammalian cells (Lilienbaum 2013) that both have been shown to be important in the aging process of RPE cells (Li et al. 2008; Kaarniranta et al. 2013 ). The UPP deals with misfolded and shortlived proteins that the chaperones cannot repair, while autophagy eliminates long-lived and aggregated proteins (Lilienbaum 2013; Kivinen et al. 2014) . Autophagy is a lysosomal catabolic mechanism in which the cell 'self eats' components that are either unnecessary or dysfunctional (Kaarniranta et al. 2011 Viiri et al. 2013; Kivinen et al. 2014) . Autophagy consists of three intracellular pathways in eukaryotic cells: (i) macroautophagy or autophagy, (ii) microautophagy and (iii) chaperone-mediated autophagy (Mizushima & Komatsu 2011) . Autophagy is triggered as an adaptive response during stress conditions such as those occurring in AMD, but it also has a significant role in normal cellular homeostasis (Kaarniranta et al. 2010; Yang & Klionsky 2010b; Klettner et al. 2013 ). The term macroautophagy refers to the formation of isolation membranes called phagophores which initiate the autophagic process. The phagophores elongate and surround those portions of cytoplasm containing the potentially harmful protein complexes and organelles leading to the formation of mature, distinct, double membrane autophagosomes. The mature autophagosomes fuse with lysosomes and the content are degraded by lysosomal enzymes (Kaarniranta et al. 2009b; Viiri et al. 2010 Viiri et al. , 2013 . The decline of autophagic capabilities represents one crucial aspect of the pathogenesis of AMD (Viiri et al. 2013) . SQSTM1/p62 (Sequestosome 1) is the best-characterized and ubiquitously expressed autophagy receptor that connects proteasomal clearance with lysosomes (Bjørkøy et al. 2005; Komatsu et al. 2007; Korolchuk et al. 2009b; Pankiv et al. 2010; Viiri et al. 2010) . Alleviation of autophagy is usually accompanied by an accumulation of SQSTM1/ p62, mostly in large perinuclear aggregates or inclusion bodies which are also positive for ubiquitin. This phenomenon has been reported to occur in numerous neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington disease (Kuusisto et al. 2001a (Kuusisto et al. , 2002 Zatloukal et al. 2002; Braak et al. 2011; Geetha et al. 2012; . Beclin-1 is conserved and it is part of a type III PI3 kinase complex (O'Brien & Wyss-Coray 2014) . This complex is crucial for the autophagic process since it is required for the formation of autophagic vesicles (Mei et al. 2014) . Therefore, an upregulation of Beclin-1 can be considered as a sign of increased autophagy activity within the cell in an attempt to restore cellular homeostasis.
Collagen XVIII is a component of basement membranes, possessing properties of both collagen and proteoglycan. Interestingly, endostatin which has anti-angiogenesis properties, is released from the collagen XVIII C-terminal domain via proteolytic cleavage. It has been speculated that collagen XVIII/ endostatin is part of the balance between pro-and antiangiogenic regulators (Marneros & Olsen 2005) . Collagen XVIII can be detected in several sites in the human eye e.g. in Bowman's membrane, the lens capsule, the trabecular network and in all the endothelial and epithelial basal membranes in both the anterior and posterior segments of the eye. On the other hand, endostatin seems to encircle the anterior chamber and the vitreous since it is localized in the surrounding structures (Ohlmann et al. 2005) . In AMD eyes, it has been showed that Bruch's membrane, RPE basal lamina, intercapillary septa and choriocapillaries all show reduced levels of endostatin (Bhutto et al. 2004) . It seems that both collagen XVIII and endostatin are essential for vision. Mutations of the Col18a1 cause the Knobloch syndrome in humans, an autosomal recessive disorder in which patients display signs of myopia, macular abnormalities, vitreoretinal degeneration and retinal detachments, sometimes accompanied by skull abnormalities (Serti e et al. 2000) . Fukai et al. showed in 2002 that Col18a1 À/À mice have a delayed regression of blood vessels along the surface of the retina in the vitreous and either a lack or an abnormal outgrowth of retinal vessels post-partum. Subsequently, it was reported that Col18a1 À/À mice display anterior ocular defects such as defective iris and atrophy of the ciliary body (Ylik€ arpp€ a et al. 2003) and massive sub-RPE deposits, abnormal RPE and agedependent loss of vision (Marneros et al. 2004 ) and these mice also have an abnormal retinal vasculature (Hurskainen et al. 2005) . Interestingly, in 2013 Aikio et al. demonstrated that the absence of the collagen XVIII short isoform led to previously described vascular abnormalities whereas the absence of either the medium or long isoforms resulted in normal retinal vascularization.
This study utilized immunohistochemical staining and confocal microscopy to evaluate the levels of the ubiquitin protein conjugate, SQSTM1/ p62 and Beclin-1 in collagen XVIII deficient mice.
Methods
Animals
The animals were born and raised in enriched environments in the laboratories of the Animal Center of University of Oulu, Oulu, Finland. The study was approved by the University of Oulu Animal Care and Use Committee. Eyes were enucleated in Oulu and shipped for the analysis to Kuopio. The oldest mice included in the study were 18 months of age representing old mice laboratory wise; Col18a1 À/À have a normal lifespan (personal communication, Prof. Taina Pihlajaniemi, University of Oulu). A total of 21 eyes from mice with collagen XVIII gene total knock-out (Col18a1 À/À ) and 20 eyes from wild type mice (control group) were included in immunohistochemical analysis. The two groups were further divided into four subgroups: (i) mice under 3 months old, (ii) 6-7 month old mice, (iii) 10-13 month old mice and (iv) 18 month old mice. The ratio of male to female mice in the knock-out group was 3:3, 0:6, 0:6 and 3:0 respectively and in the control group 3:3, 4:2, 0:5 and 3:0 respectively. In addition, 3 sample sections from each studied eye were selected for the staining, making a combined total of 63 of samples in the knock-out group and 60 in the control group.
Immunohistochemistry for light microscopy
The mice were euthanized with an overdose of sodium pentobarbitone (120 mg/kg) and were killed by cervical dislocation. The eyes were immediately enucleated and placed in a phosphatebuffered saline (PBS) bath (pH 7.4). Next, the eyes were cut in half and fixed immediately, dehydrated in a graded series of ethanol and embedded in paraffin at 54°C. Serial sections of 5 mm thickness were made in the horizontal plane and processed for later immunohistochemical evaluation.
Immunohistochemistry was carried out similarly to our previous work with human cadaver samples (Viiri et al. 2013) . Deparaffinized and rehydrated tissue sections were immunostained for SQSTM1/p62, ubiquitin (ub) and Beclin-1. The stainings were conducted with the Thermo Scientific's UltraVision LP Detection System AP Polymer & Fast Red Chromogen (TL-015-AF) kit according to the manufacturer's instructions. The antibodies used were mouse monoclonal for SQSTM1/p62 (Abcam #ab76340), rabbit polyclonal for ub (Dako, Z0458) and the rabbit polyclonal for Beclin-1 (Novus Biologicals, Cambridge, UK, NB500-249). The dilutions used were 1:250, 1:500 and 1:400 respectively. After the staining, the samples were analyzed as described above, photomicrographs were taken in a Zeiss AX10 Imager A2 (G€ ottingen) light microscope with a Jenoptik ProgRes C5 (Optical Systems) digital camera mounted onto the microscope and images were processed using Adobe Photoshop CS4 (Adobe Systems Inc., San Jose, CA, USA). The extent of immunopositivity in a subjective view in the cytoplasm, basal part and nuclei of the retinal pigment epithelial cells in relation to the whole length of the RPE was evaluated microscopically. Immunoprecipitation was evaluated independently using randomly selected immunostained samples from each individual case (N = 3): on a scale from 0 to +++, in which 0 represents no staining, +/À sporadic, + mild, ++ moderate and +++ extensive staining. These were later given a numeric value of 0, 0.5, 1, 2 and 3 respectively, prior to the statistical analysis. According to the histological anatomy, all the horizontal sections were assessed from the corneal level. The statistical analysis for the results was conducted with a Mann-Whitney test in the SPSS Statistics 19.0 program (IBM SPSS Inc).
Immunohistochemistry for confocal light microscopy
A total of 6 female/male mice (3 wild types and 3 Col18a1 À/À ) at 18 months of age were used for this study. After dewaxing and rehydration, the triple labeling of the retina was performed according to previously published methods, with minor modifications. These antibodies had been successfully used in our previous studies and have been well characterized by other investigators and can be considered as specific biomarkers of the UPP system and autophagy-lysosomal pathways (Bjørkøy et al. 2005; Komatsu et al. 2007; Korolchuk et al. 2009b; Pankiv et al. 2010; Viiri et al. 2010; Lilienbaum 2013; O'Brien & Wyss-Coray 2014) . Briefly, the sections were incubated in humidity chambers with 1% bovine serum albumin (Sigma, St. Louis, MO, USA) and 0.2% Triton-X in PBS for two nights with a mixture primary antibodies including anti-Ubiquitin (diluted 1:250/DAKO, Glostrup, Denmark) and SQSTM1/p62 (diluted 1:150/Progen, Heidelberg, Germany) and anti-Beclin-1 (diluted 1:100/Novus Biologicals) at 4°C. After rinsing, the primary antibodies in PBS section were than incubated with a cocktail of secondary antibodies as follows: Alexa Fluor 488 anti-mouse, Alexa Fluor 647 anti-guinea pig/Invitrogen, Camarillo, CA, USA/and Alexa 546 anti-rabbit/ Molecular Probes, Grand Island, NY, USA) has been used for 2 hrs at room temperature in 1/250 dilution. A fluorescent nuclear marker was diluted (DAPI, 4,6-diamidino-2-phenylindole, dihydrochloride;
1:1000/Molecular Probes, Camarillo, CA, USA) in PBS containing 0.1% saponin for 30 min and covered with Vectashield mounting Media (Vector Laboratories, Burlingame, CA, USA). The long incubation period with the primary antibodies was necessary to enhance the permeation of the antibodies into the sections and to ensure constant and sufficient quality of the confocal images in the different sections. The validity of the sequential staining was then verified with the same protocol as described above except that one of the primary antibodies was omitted. The negative control samples displayed only a sub-minimal autofluorescent signal.
Confocal microscopic analysis
The sections were examined with a confocal laser-scanning microscope (Olympus, Tokyo, Japan) that was equipped a multiline Ar laser (458, 488 and 514 nm), an HeNe(G) laser (543 nm) and an HeNe(R) laser (633 nm). Images were obtained sequentially from the green, red, and far-red channels on optical slices of 1 lm of thickness using a 609 oil immersion objective (NA:1.42, Plan Apochromat). The confocal settings were identical for all scans and kept constant during imaging. Representative scans were taken with Fluoview ASW 3.1 software and processed with Adobe Photoshop CS6 software. In all imaging procedures, gamma adjustment was done in the whole image in order to maintain appropriate contrast.
Results
Previous documents show intra-and extracellular protein deposits in Col18a1 À/À mice and AMD samples (Fukai et al. 2002; Ylik€ arpp€ a et al. 2003; Marneros et al. 2004; Viiri et al. 2013) . Therefore, our analysis focused not only on the nuclei, cytoplasm and basal parts of the RPE cells, but also on the extracellular space.
Ubiquitin (ub) protein conjugate staining in the cytoplasm of wild type RPE cells was at the mild or moderate level from the age of 3-13 months, while the ub staining was clearly decreased in the oldest (18 month) group (Table 6 ). The specimens from the knock-out mice showed only sporadic or mild staining. A statistically significant difference (p < 0.05) was observed in the extent of cytoplasm staining for ub between knock-out and wild type specimens from the 3 and 6-7 month old mice. In contrast to samples from the wild-type animals, the knock-out mice showed increased age-related ub stainings of the RPE cell basal part (Fig. 30) . All basal part ub staining differences were statistically significantly different (p < 0.01 for 3 months, p < 0.05 for 6-7 month, p < 0.001 for 10-13 months and p < 0.01 for 18 months) when compared between knock-out and wild type animals. The nuclei of RPE cells exhibited statistically stronger ub staining in the wild-type animals in the 6-7 and 10-13 month old groups (p < 0.05).
With respect to SQSTM1/p62, the cytoplasms of the RPE cells were mostly negative in both knock-outs and wild types and no statistical difference was observed between any of the groups studied ( Fig. 30 and Table 7 ). Some sporadic staining of the basal part deposit for p62 was observed in all of the groups studied. A statistically significant difference was observed between knock-outs and wild types in the 10-13 month old mice (p < 0.05). The nuclei of the RPE cells showed sporadic staining for p62 with no statistically significant difference between the groups.
Beclin-1 staining of the cytoplasm of the wild type RPE cells exhibited sporadic to moderate staining in all of the groups studied (Table 8 ). In contrast, the cytoplasm of the knock-out cells revealed sporadic staining in specimens from mice 10-13 month old and younger but extensive staining in 18 month old mice for Beclin-1. A statistically significant difference was observed in cytoplasm staining for Beclin-1 between knock-outs and wild types in the groups of 3 month, 6-7 month and 18 month old mice (p < 0.05 in all groups). The difference between the groups of 10-13 month old mice was not statistically significant, although the data was consistent with that found in the other groups. The deposits in the basal part showed mild to almost extensive staining for Beclin-1 in the knock-out specimens (Fig. 30) . In contrast, only sporadic staining was observed in the Table 6 . Immunohistochemistry for ubiquitin. The cytoplasm of RPE cells showed mild to moderate staining in all age-groups except for the 18 month old mice in wild types whereas the knock-outs showed only sporadic to mild staining. A statistically significant difference was observed in groups A* and B*. Knock-outs in groups A and B showed sporadic staining of basal part deposits but groups C and D showed almost moderate to extensive staining; these differences were statistically significant (A**, B*, C*** and D**). The nuclei of RPE cells displayed mild to moderate staining in specimens from wild type mice. In the knock-out mice, the staining was sporadic to moderate. The difference in groups B* and C* was statistically significant. corresponding samples from the wild type animals. A statistically significant difference between knock-outs and wild types was observed in all of the studied groups (p < 0.05 for 3 months, p < 0.05 for 6-7 months, p < 0.01 for 10-13 months and p < 0.01 for 18 month old mice). The nuclei of RPE cells for both wild types and knock-outs displayed sporadic staining for Beclin-1 with no statistical difference between the groups. In the comparison of the RPE cells from the wild type and knock-out animals, we observed degeneration of the RPE and overall morphology of the tissue in the knock-outs (Fig. 29) . In contrast, the cells from the wild type mice appeared to be rather normal. We also observed a clearly visible sub-RPE deposit, similar to that described by Marneros et al. in 2004, in Col18a1 À/À mice but not in the wild type animals. The location within the tissue and subcellular localization of studied autophagy markers was investigated further by confocal microscopy imaging.
In all of the samples analysed, confocal microscopy revealed that the ub protein conjugates, multifunctional scaffold protein SQSTM1/p62 and Beclin-1 were found in intracellular structures of varying sizes in the basal part of RPE cells (Fig. 31) . The single plane image revealed that perinuclear structures were strongly SQSTM1/p62 and Beclin-1 positive, while ub and SQSTM1/p62 were found to localize to Bruch's membrane. The positive, but faintly detectable, fluorescent small vesicles were mainly spherical, whereas the larger structures were more irregularly shaped and included spherical and oval-shaped structures. We also detected colocalization of ub and Beclin-1 positive discrete fluorescent structures, mostly within the larger structures rather than inside the smaller vesicles, but small SQSTM1/p62-stained vesicles in the cytosol and Bruch's membrane were not colocalized. The negative control samples revealed only a minimal autofluorescent signal (data not shown).
No differences between female or male mice was detected in neither wild types nor in knock-outs.
Discussion
Endostatin has been shown to inhibit VEGF production in two ways; first by blocking the proliferation of the choroid-retinal endothelial cells by limiting the progression of the cell cycle and second by preventing their migration (Xu et al. 2010) . Moreover, endostatin reduces the expression of the inflammatory mediator tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinases (MMPs) and vascular cell adhesion molecule-1 (VCAM-1). Interestingly, endostatin also induces autophagy via the upregulation of Beclin-1 (Nguyen et al. 2009 ). Endostatin, a fragment formed during the elimination of the collagen XVIII Cterminus, evokes AMD-like deposits and RPE degeneration in our animal model (Fukai et al. 2002; Ylik€ arpp€ a et al. 2003; Marneros et al. 2004 ). Here we found that Col18a1 À/À mice display a dysfunctional autophagy flux as observed by increased staining levels of ub, SQSTM1/p62 and Beclin-1.
The extracellular deposits are ub positive as is the case in human AMD material (Mullins et al. 2000; Viiri et al. 2013 ). The accumulation of ubiquitin-marked proteins is often used as evidence for proteasome inhibition. Lysosomal autophagy is a central clearance system functioning together with the proteasomes (Ferrington et al. 2016 ). The formation of the autophagosome from the phagophore can be divided into four different phases, i.e. initiation, nucleation, elongation and sealing steps (Klionsky & Schulman 2014; Klionsky et al. 2016 ). Subsequently, the autophagosomes mature and fuse with endosomes and lysosomes and finally the sequestered material is degraded inside autolysosomes. The formation of the autophagosome is tightly controlled by the assembly of Atg proteins into five different complexes, which sequentially organize the construction of autophagosomes. These core complexes include (i) ULK1 protein kinase complex, (ii) Beclin 1-Vps34 lipid kinase complex, (iii) Atg9-WIPI-1 complex, (iv) Atg12 conjugation system, and (v) LC3 lipidation system . This is the first time that ub protein aggregates have been found to be increased not only within RPE cells but also in the extracellular space, evidence for disturbed proteostasis during the aging process in the absence of collagen XVIII. Beclin-1 is one of the most widely used markers of the activation of the formation of the autophagosome (Klionsky et al. 2016) . We believe that autophagy is an important homeostatic clearance system which promotes the survival of the RPE cells. In aged knock-out animals, in conjunction with the observed cellular damage, the upregulation of Beclin-1 formation and the induction of autophagy may be a compensatory response attempting to salvage the RPE cells. However, the activity of autophagic processes decreases with aging in RPE cells (Rodr ıguez-Muela et al. 2013; Viiri et al. 2013; Mitter et al. 2014; Toops et al. 2015; Yao et al. 2015) . One explanation for this decreased autophagy might be the accumulation of lipofuscin, a hallmark of aging; this protein is known to suppress lysosomal function and autophagic clearance in RPE cells Krohne et al. 2010a; Viiri et al. 2013; Mitter et al. 2014; Valapala et al. 2014; Zhang et al. 2015) . Autophagy may regulate the traffic of intracellular proteins in exosomes into the extracellular space, which probably contributes to drusen formation (Wang et al. 2009b; Kannan et al. 2016) . SQSTM1/p62 is called the autophagy receptor, which can also be used as a protein marker for autophagy flux, at least in certain settings (Klionsky et al. 2016 ). The SQSTM1 protein serves as a link between LC3 and ubiquitinated substrates (Pankiv et al. 2007 ). SQSTM1/p62 and its polyubiquitinated proteins become incorporated into the mature autophagosome and are degraded in autolysosomes, thus Table 8 . Immunohistochemistry for Beclin-1. The cytoplasms of RPE cells showed sporadic to moderate staining in specimens from the wild type mice whereas the corresponding knock-outs showed only sporadic staining in the groups 10-13 months and younger but almost extensive staining in 18 months old mice. The differences were statistically significant between groups A*, B* and D*, and group C data showed a similar, but not statistically significant, trend. The basal part deposits showed mild to almost extensive staining in all the knock-out specimens. The wild types showed only sporadic staining. The difference was statistically significant in all groups (A*, B*, C** and D**). The nuclei of RPE cells showed only sporadic to mild staining in both wild types and knock-outs and no statistically significant difference was detected. representing an index of autophagic degradation (Viiri et al. 2010 (Viiri et al. , 2013 Kivinen et al. 2014; Klionsky et al. 2016 ). The extent of inhibition of autophagy correlates with increased levels of SQSTM1/p62 suggesting that steady state levels of this protein reflect the autophagic status. Similarly, decreased SQSTM1 levels are associated with autophagy activation (Klionsky et al. 2016 ). The upregulation of SQSTM1/p62 has also been associated with increased oxidative stress and inhibition of proteasome activity in RPE cells (Viiri et al. 2010; Wang et al. 2014 Wang et al. , 2016 Johansson et al. 2015) .
Retinal pigment epithelium (RPE) cells are continually exposed to oxidative stress that contributes to protein misfolding, aggregation and functional abnormalities during aging. The protein aggregates formed at the cell periphery are transferred along the microtubules network by dyneindependent retrograde trafficking to a juxtanuclear location (Boyault et al. 2007) . In this study, we observed increased staining for ub protein conjugates, SQSTM1/p62 and Beclin-1 in the basal perinuclear part in the aged knock-out mice, evidence of the formation of aggresomes, in line with our previous works Viiri et al. 2010 Viiri et al. , 2013 . As far as we are aware, this is the first study to demonstrate SQSTM1/p62 staining in the extracellular space of RPE cells. Since autophagy also ensures selective clearance and participation in exocytosis (Xu & Ren 2015) , it may be speculated that increased protein aggregation and the decline in autophagy both contribute to the exosomal protein export into the extracellular space (Wang et al. 2009b; Xu & Ren 2015) . The extracellular staining of SQSTM/p62 was however weak and therefore more studies will be required to clarify how it is trafficked to this location.
The collagen XVIII knock-out mouse represents a novel model with which to study the role of proteostasis in the degeneration of RPE, and the proteins involved in autophagy as therapeutic targets in the search for novel ways to combat age-related damage to RPE cells.
General Discussion
Summary
In the developed countries, common vision-threatening conditions such as cataracts, glaucomas and refractive errors can be nowadays efficiently treated. Thus, age-related macular degeneration is the leading cause of irreversible blindness. Pathophysiologically, AMD is associated with oxidative stress and chronic inflammation (Jarrett & Boulton 2012; Ambati et al. 2013; Piippo et al. 2014) . However, there is increasing evidence suggesting that dysfunctional cellular proteostasis ultimately leads to protein aggregation and contributes to the development of AMD. The dysregulation of autophagy has a crucial role in this process as it predisposes the RPE to protein aggregation (Mitter et al. 2014) .
Pigment epithelium cells (RPE) cells have an efficient autophagic protein clearance system ). When treated with a lysosomal inhibitor, bafilomycin, autophagosome formation and SQSTM1/p62 accumulation are observed indicating the presence of dysfunctional autophagy (Viiri et al. 2010 ). As we demonstrated, this accumulation of SQSTM1/ p62 is not detected when the posttranscriptional factor ELAVL1/HuR is removed. Further, if there is proteasome inhibition, then the administration of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) activated autophagy clearance and a decrease of SQSTM1/p62 levels was observed. In addition, in this experiment SQSTM1/ p62 was localized within perinuclear aggregates, indicating that SQSTM1/ p62 is cleared by autophagocytosis. Thus it is proposed SQSTM1/p62 can be used as a marker for impaired autophagy (Publication I).
We observed increased levels of SQSTM1/p62 in macular regions of human cadaver samples. Perimacular and peripheral areas of cadaver samples (the internal control) and age-matched controls did not show any signs of an increase in SQSTM1/ p62 levels. We did detect age-related changes (e.g. drusen) in the perimacular and peripheral areas. Interestingly, ubiquitin upregulation was observed in those areas as well as in macular areas and no differences between these groups were noted. This indicates that these regions still have an active and normally functioning UPP (Ubiquitinproteasome pathway) system. Macular regions are subjected to light induced damage and are more metabolically active compared to the peripheral regions due to their higher concentration of light receptor cells. Thus, a dysregulation of autophagy may primarily affect these regions, especially in conditions when other systems controlling cellular proteostasis, such as the functions of Hsps, are unable to cope with the amounts of damaged proteins. Our findings suggest that impaired autophagy may have a substantial role in the pathogenesis of AMD (Publication I).
Molecular chaperones are the first line of defence against the harmful proteins generated by cellular stress. We studied the relationship of the chaperone Hsp70 and autophagocytosis in vitro. Using the same methods as applied in Publication I, we demonstrated that Hsp70 did not undergo autophagic clearance during UPP inhibition and that its levels in cells were not affected by proteasome inhibition or inhibition of autophagy. Thus, it is concluded that Hsp70 is protected from autophagic clearance and exerts a cytoprotective role that is not connected to UPP or LPP. As Hsps are known to mediate autophagy and regulate inflammatory responses (e.g. by participating in cytokine signal transduction; Moseley 1998; Kaarniranta et al. 2009b; Yang et al. 2009) , it is possible that they could be a therapeutic target in AMD and perhaps also in similar neurodegenerative diseases, such as AD (Klettner 2004) . Upregulation of Hsp70 either by gene, drug or laser therapy may activate autophagy of RPE cells, maintain lysosomal enzymes functional and thus prevent protein aggregation (Karlsson et al. 2013, Publication II) .
In Publication III, we evaluated the effect of the current standard-of-care for wet AMD i.e. aVEGF-therapy agent, bevacizumab [K€ ayp€ a hoito: Kostea silm€ anpohjan ik€ arappeuma 2016 (Finnish Current Care Guideline: Wet AMD 2016)] on the autophagy activity of RPE cells. It was noted that bevacizumab did not exert any effect on autophagy clearance during UPP inhibition or accumulation of protein aggregates indicating that this agent was not altering the autophagic activity of RPE cells. We also compared a lysosomal inhibitor, bafilomycin, and bevacizumab with both short and longterm exposures. Our data suggests that bevacizumab does not disturb autophagic clearance of RPE cells, which supports bevacizumab's safe use in AMD at the cellular level (Publication III).
To date several potential animal models for AMD have been introduced (Pennesi et al. 2012 ). The problem is that their phenotype usually only encompasses a part of the features found in AMD, e.g. excess oxidative stress. We studied the presence of a proteasome marker ubiquitin and two autophagy markers SQSTM1/p62 and Beclin-1 in the eyes of collagen 18 knock-out mice. We observed that these mice showed evidence of dysfunctional autophagic flux, indicating that these animals may represent a novel model for AMD. Interestingly, we made a novel finding, the detection of SQSTM1/p62 immunostaining in the extracellular space of RPE cells. It is possible that the massive protein aggregation observed with decreased autophagy activity leads to the export of proteins in to the extracellular space by exosomal transportation as a final attempt to maintain cellular homeostasis (Publication IV). Alternatively, this may due to apoptosis or it may be a novel and still unknown route of cell signalling between individual RPE cells. Further studies will be necessary to clarify these cellular events.
Limitations of the study
We mostly used RPE cell cultures and animal models in these studies. AMD in humans takes years, even decades, to develop whereas cell cultures might only live for days or weeks. In addition, the most widely used experimental animals do not have a macula. While experiments conducted in cells or experimental animals can provide insights into the mechanisms behind different pathological conditions in controlled environments, it is obvious that these results obtained cannot be unconditionally extrapolated to physiology of human vision or to the pathophysiology of AMD. Due to this fact, there is no consensus of the fundamental pathological feature behind AMD.
Since other aVEGF agents are also on the market (ranibizumab and aflibercept), it would have been interesting to incorporate these compounds into the study design. A similar study which utilized fibroblasts present in CNV found that four aVEGF therapeutic agents (ranibizumab, bevacizumab, pegaptanib, and aflibercept) could inhibit cellular proliferation but showed higher apoptotic activity dosedependently. Interestingly, there was the appearance of vacuoles in the cytoplasms and increased levels of LC3 I and II indicative of the induction of autophagy (Lytvynchuk et al. 2015) . As autophagy has a role in maintaining cellular homeostasis and in caspaseindependent cellular death (Lin & Baehrecke 2015) , this finding may be evidence that there had been induction of autophagic death in these cells. Clearly, further studies with RPE cells should be conducted.
Only 8 cadaver samples from AMD patients were used in this study and with the Col18a1 À/À mice we also faced difficulties with obtaining sufficient sample materials. Human specimens are hard to obtain due to legislative and ethical reasons. We received the harvested murine eyes prefixed. Unfortunately, there were some problems with the fixation, leading to some samples being damaged.
To further evaluate the possibilities of Col18a1 À/À mice as an AMD model, a quantitative analysis of the proteins of interest by Western blotting and mRNA quantification would have provided further information. Unfortunately, Col18a1 À/À cell lines are not commercially available. We considered but then rejected the possibility of microsurgically isolating the RPE from these mice. Microsurgical isolation, even if performed extremely carefully, would invariably lead to the presence of some extra (i.e. non-RPE) tissue in the sample leading to experimental artefacts in any data. Information about the presence of the proteins of interest from patients with Knobloch syndrome would also provide additional information about the applicability of our findings.
Future directions
At present, we can only offer treatment to about one in ten AMD patients and even in these cases, the treatment is not curative. A fundamental comprehension of the pathogenesis of AMD is needed in order to develop effective and curative treatments. The current data indicates that a dysfunction of autophagy is an essential component in the pathogenesis AMD. The information gathered in this thesis project will hopefully act as a springboard for future studies with larger sample volumes allowing more extensive assay of relevant targets. Clearly more data from studies utilizing human samples would be especially illuminating.
To end on a positive note, several trials with promising therapeutics are currently in clinical trials and hopefully at least some of them will emerge as future therapies for AMD.
Conclusions
1 SQSTM1/p62 is a good marker of impaired autophagy. Impaired autophagy seems to have a great role in AMD pathology. 2 Cellular chaperone Hsp70 is not degraded by autophagy and it could be used as a therapy target in the treatment of AMD. 3 The current standard-of-care for wet AMD (bevacizumab) does not interfere with autophagy in any level. 4 Collagen XVIII total knock-out mouse with its AMD-like changes in the RPE is a novel but a potential model for AMD.
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